An	O
essential	O
role	O
for	O
NF-kappaB	B-protein
in	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cell	I-cell_type
survival	O
.	O

The	O
transcription	B-protein
factor	I-protein
,	O
NF-kappaB	B-protein
,	O
is	O
important	O
for	O
T-cell	O
activation	O
,	O
B-cell	O
maturation	O
,	O
and	O
human	O
immunodeficiency	O
virus	O
transcription	O
and	O
plays	O
a	O
role	O
in	O
alternatively	O
mediating	O
and	O
protecting	O
against	O
apoptosis	O
in	O
a	O
variety	O
of	O
cell	O
types	O
.	O

However	O
,	O
a	O
role	O
for	O
NF-kappaB	B-protein
in	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
has	O
not	O
been	O
described	O
.	O

We	O
provide	O
evidence	O
here	O
that	O
virtually	O
all	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
express	O
NF-kappaB	B-protein
that	O
can	O
be	O
activated	O
by	O
exposure	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
a	O
variety	O
of	O
cytokines	B-protein
,	O
eg	O
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
,	O
interleukin-3	B-protein
,	O
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
NF-kappaB	B-protein
may	O
be	O
required	O
for	O
human	O
CD34	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cell	I-cell_type
clonogenic	O
function	O
and	O
survival	O
.	O

These	O
results	O
offer	O
insight	O
into	O
a	O
new	O
role	O
for	O
NF-kappaB	B-protein
in	O
maintaining	O
survival	O
and	O
function	O
in	O
hematopoietic	B-cell_type
stem	I-cell_type
and	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
and	O
suggest	O
that	O
proposed	O
strategies	O
involving	O
inhibition	O
of	O
NF-kappaB	B-protein
activation	O
as	O
an	O
adjunct	O
to	O
cancer	O
chemotherapy	O
should	O
be	O
approached	O
with	O
caution	O
.	O

HEMATOPOIESIS	NULL
An	NULL
Essential	NULL
Role	NULL
for	NULL
NF-xB	NULL
in	NULL
Human	NULL
CD34¢	NULL
Bone	NULL
Marrow	NULL
Cell	NULL
Survival	NULL
By	NULL
David	NULL
W.	NULL
Pyatt	NULL
,	NULL
Wayne	NULL
S.	NULL
Stillman	NULL
,	NULL
Yanzhu	NULL
Yang	NULL
,	NULL
Sherilyn	NULL
Gross	NULL
,	NULL
Jia	NULL
hua	NULL
Zheng	NULL
,	NULL
and	NULL
Richard	NULL
D.	NULL
Irons	NULL
The	NULL
transcription	NULL
factor	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
is	NULL
important	NULL
for	NULL
T-cell	NULL
activation	NULL
,	NULL
B-cell	NULL
maturation	NULL
,	NULL
and	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
transcription	NULL
and	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
alternatively	NULL
mediating	NULL
and	NULL
protecting	NULL
against	NULL
apoptosis	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
.	NULL

However	NULL
,	NULL
a	NULL
role	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
human	NULL
CD34+*	NULL
bone	NULL
marrow	NULL
cells	NULL
has	NULL
not	NULL
been	NULL
described	NULL
.	NULL

We	NULL
provide	NULL
evidence	NULL
here	NULL
that	NULL
virtually	NULL
all	NULL
human	NULL
CD34+	NULL
bone	NULL
marrow	NULL
cells	NULL
express	NULL
NF-	NULL
«	NULL
B	NULL
that	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
exposure	NULL
to	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
and	NULL
a	NULL
variety	NULL
of	NULL
cytokines	NULL
,	NULL
eg	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
,	NULL
interleukin-3	NULL
,	NULL
and	NULL
granulocyte-macrophage	NULL
colony	NULL
F-	NULL
«	NULL
B	NULL
IS	NULL
A	NULL
MEMBER	NULL
of	NULL
the	NULL
mammalian	NULL
Rel	NULL
family	NULL
of	NULL
transcriptional	NULL
activators	NULL
that	NULL
plays	NULL
a	NULL
central	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
and	NULL
regulation	NULL
of	NULL
immune	NULL
response	NULL
.	NULL

!	NULL

The	NULL
family	NULL
consists	NULL
of	NULL
5	NULL
discrete	NULL
DNA	NULL
binding	NULL
proteins	NULL
(	NULL
p50	NULL
,	NULL
p52	NULL
,	NULL
p65	NULL
,	NULL
c-rel	NULL
,	NULL
and	NULL
ReIB	NULL
)	NULL
that	NULL
share	NULL
partial	NULL
homology	NULL
,	NULL
including	NULL
a	NULL
common	NULL
DNA	NULL
binding	NULL
domain	NULL
,	NULL
dimerization	NULL
domains	NULL
,	NULL
and	NULL
a	NULL
nuclear	NULL
localization	NULL
region	NULL
.	NULL

Rel	NULL
family	NULL
members	NULL
form	NULL
ho-modimers	NULL
or	NULL
heterodimers	NULL
that	NULL
bind	NULL
to	NULL
a	NULL
specific	NULL
DNA	NULL
sequence	NULL
called	NULL
the	NULL
xB	NULL
motif	NULL
.	NULL
``	NULL

NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
heterodimer	NULL
consisting	NULL
of	NULL
the	NULL
50-kD	NULL
(	NULL
p50	NULL
)	NULL
and	NULL
65-kD	NULL
(	NULL
p65	NULL
)	NULL
subunits®	NULL
that	NULL
,	NULL
in	NULL
its	NULL
inactive	NULL
state	NULL
,	NULL
is	NULL
located	NULL
in	NULL
the	NULL
cytoplasm	NULL
bound	NULL
to	NULL
an	NULL
inhibitory	NULL
protein	NULL
,	NULL
IxBa	NULL
.	NULL
``	NULL

''	NULL
Upon	NULL
activation	NULL
,	NULL
NF-KB	NULL
disassociates	NULL
from	NULL
translocates	NULL
to	NULL
the	NULL
nucleus	NULL
``	NULL
and	NULL
binds	NULL
to	NULL
DNA	NULL
to	NULL
regulate	NULL
gene	NULL
expression	NULL
(	NULL
for	NULL
review	NULL
see	NULL
Thanos	NULL
and	NULL
Maniatis®	NULL
and	NULL
Siebenlist	NULL
et	NULL
al	NULL
``	NULL
?	NULL
)	NULL

.	NULL

Additionally	NULL
,	NULL
complex	NULL
binding	NULL
patterns	NULL
among	NULL
various	NULL
members	NULL
of	NULL
the	NULL
Rel	NULL
family	NULL
may	NULL
account	NULL
for	NULL
differential	NULL
gene	NULL
activation	NULL
with	NULL
or	NULL
without	NULL
interaction	NULL
with	NULL
other	NULL
transcriptional	NULL
regulatory	NULL
proteins	NULL
.	NULL
``	NULL

NF-KB	NULL
is	NULL
required	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
several	NULL
gene	NULL
products	NULL
relevant	NULL
to	NULL
hematopoiesis	NULL
including	NULL
interleukin-1B	NULL
(	NULL
IL-1B	NULL
)	NULL
,	NULL
``	NULL
tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
(	NULL
TNF-a	NULL
)	NULL
,	NULL
!	NULL

4	NULL
IL-6	NULL
,	NULL
``	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
M-CSF	NULL
)	NULL
,	NULL
!	NULL

®	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
,	NULL
``	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
G-CSF	NULL
)	NULL
,	NULL
!	NULL
``	NULL

erythropoietin	NULL
(	NULL
EPO	NULL
)	NULL
,	NULL
``	NULL
interferon-y	NULL
(	NULL
INF-	NULL
From	NULL
The	NULL
Molecular	NULL
Toxicology	NULL
and	NULL
Environmental	NULL
Health	NULL
Sciences	NULL
Center	NULL
,	NULL
School	NULL
of	NULL
Pharmacy	NULL
,	NULL
the	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
and	NULL
the	NULL
Cancer	NULL
Center	NULL
,	NULL
University	NULL
of	NULL
Colorado	NULL
Health	NULL
Sciences	NULL
Center	NULL
,	NULL
Denver	NULL
,	NULL
CO	NULL
.	NULL

Submitted	NULL
March	NULL
16	NULL
,	NULL
1998	NULL
;	NULL
accepted	NULL
January	NULL
7	NULL
,	NULL
1999	NULL
.	NULL

Supported	NULL
by	NULL
Grant	NULL
No	NULL
.	NULL

ESO6258	NULL
from	NULL
the	NULL
National	NULL
Institute	NULL
of	NULL
Environmental	NULL
Health	NULL
Sciences	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
NIH	NULL
)	NULL
and	NULL
its	NULL
contents	NULL
are	NULL
solely	NULL
the	NULL
responsibility	NULL
of	NULL
the	NULL
authors	NULL
and	NULL
do	NULL
not	NULL
necessarily	NULL
represent	NULL
the	NULL
official	NULL
views	NULL
of	NULL
the	NULL
NIEHS	NULL
,	NULL
NIH	NULL
.	NULL

This	NULL
publication	NULL
was	NULL
also	NULL
made	NULL
possible	NULL
by	NULL
the	NULL
cooperation	NULL
and	NULL
support	NULL
of	NULL
University	NULL
of	NULL
Colorado	NULL
Cancer	NULL
Center	NULL
Flow	NULL
Cytometry	NULL
Core	NULL
(	NULL
Grant	NULL
No	NULL
.	NULL

2	NULL
P30	NULL
CA	NULL
46934-09	NULL
)	NULL
and	NULL
the	NULL
Clinical	NULL
Investigation	NULL
Core	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Richard	NULL
D.	NULL
Irons	NULL
,	NULL
PhD	NULL
,	NULL
D.A.B.T	NULL
,	NULL
University	NULL
of	NULL
Colorado	NULL
Health	NULL
Sciences	NULL
Center	NULL
,	NULL
4200	NULL
E.	NULL
9th	NULL
Ave	NULL
,	NULL
Box	NULL
C238	NULL
,	NULL
Denver	NULL
,	NULL
CO	NULL
80262	NULL
;	NULL
e-mail	NULL
:	NULL
Richard	NULL
.	NULL

Irons	NULL
@	NULL
UCHSC.edu	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
adver-tisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-4971/99/9310-0008	NULL
$	NULL
3.00/0	NULL
3302	NULL
stimulating	NULL
factor	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
may	NULL
be	NULL
required	NULL
for	NULL
human	NULL
CD34+	NULL
bone	NULL
marrow	NULL
cell	NULL
clonogenic	NULL
function	NULL
and	NULL
survival	NULL
.	NULL

These	NULL
results	NULL
offer	NULL
insight	NULL
into	NULL
a	NULL
new	NULL
role	NULL
for	NULL
NF-kB	NULL
in	NULL
maintaining	NULL
survival	NULL
and	NULL
function	NULL
in	NULL
hematopoietic	NULL
stem	NULL
and	NULL
progenitor	NULL
cells	NULL
and	NULL
suggest	NULL
that	NULL
proposed	NULL
strategies	NULL
involving	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
as	NULL
an	NULL
adjunct	NULL
to	NULL
cancer	NULL
chemotherapy	NULL
should	NULL
be	NULL
approached	NULL
with	NULL
caution	NULL
.	NULL

©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

y	NULL
)	NULL
,	NULL
``	NULL
°	NULL
c-myc	NULL
,	NULL
``	NULL
and	NULL
c-myb	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
is	NULL
activated	NULL
by	NULL
cytokines	NULL
known	NULL
to	NULL
regulate	NULL
hematopoiesis	NULL
such	NULL
as	NULL
TNF-	NULL
«	NULL
,	NULL
``	NULL
``	NULL
IL-la	NULL
and	NULL
IL-1B	NULL
,	NULL
*	NULL
INF-y	NULL
,	NULL
``	NULL
leukemia	NULL
inhibitory	NULL
factor	NULL
,	NULL
``	NULL
``	NULL
M-CSF	NULL
``	NULL
GM-CSF	NULL
,	NULL
``	NULL
transforming	NULL
growth	NULL
factor-	NULL
B1	NULL
(	NULL
TGF-B1	NULL
)	NULL
,	NULL
*°	NULL
and	NULL
IL-3	NULL
.	NULL
``	NULL

The	NULL
role	NULL
of	NULL
NF-KB	NULL
as	NULL
a	NULL
secondary	NULL
messenger	NULL
for	NULL
cytokine	NULL
response	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
hematopoiesis-specific	NULL
genes	NULL
that	NULL
are	NULL
responsive	NULL
to	NULL
NF-KB	NULL
,	NULL
suggest	NULL
that	NULL
it	NULL
may	NULL
be	NULL
important	NULL
in	NULL
human	NULL
CD34	NULL
*	NULL
cell	NULL
survival	NULL
and/or	NULL
differentiation	NULL
.	NULL

Studies	NULL
with	NULL
disruption	NULL
of	NULL
the	NULL
various	NULL
Rel	NULL
family	NULL
proteins	NULL
support	NULL
this	NULL
observation	NULL
.	NULL

The	NULL
disruption	NULL
of	NULL
the	NULL
re/A4	NULL
locus	NULL
(	NULL
p65	NULL
)	NULL
leads	NULL
to	NULL
embryonic	NULL
lethality	NULL
at	NULL
15	NULL
to	NULL
16	NULL
days	NULL
of	NULL
gestation	NULL
with	NULL
massive	NULL
liver	NULL
degeneration	NULL
.	NULL

``	NULL
?	NULL

Mice	NULL
with	NULL
homozygous	NULL
disruption	NULL
of	NULL
relB	NULL
exhibit	NULL
multifocal	NULL
,	NULL
mixed	NULL
inflammatory	NULL
cell	NULL
infiltration	NULL
in	NULL
several	NULL
organs	NULL
,	NULL
myeloid	NULL
hyperplasia	NULL
,	NULL
splenomegaly	NULL
due	NULL
to	NULL
extramedullary	NULL
hematopoiesis	NULL
,	NULL
a	NULL
reduced	NULL
number	NULL
of	NULL
thymic	NULL
dendritic	NULL
cells	NULL
,	NULL
and	NULL
impaired	NULL
cellular	NULL
immunity	NULL
.	NULL
``	NULL

'	NULL
Mice	NULL
lacking	NULL
p50	NULL
show	NULL
no	NULL
developmental	NULL
abnormalities	NULL
,	NULL
but	NULL
have	NULL
impaired	NULL
B-cell	NULL
responses	NULL
.	NULL
``	NULL

Mice	NULL
with	NULL
constitutive	NULL
NF-kB	NULL
activation	NULL
due	NULL
to	NULL
the	NULL
disruption	NULL
of	NULL
IxBa	NULL
expression	NULL
show	NULL
enhanced	NULL
granulopoiesis	NULL
and	NULL
die	NULL
within	NULL
8	NULL
days	NULL
after	NULL
birth	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
both	NULL
apoptosis	NULL
and	NULL
anti-apoptotic	NULL
functions	NULL
can	NULL
be	NULL
mediated	NULL
via	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
different	NULL
cells.3+	NULL
``	NULL
5	NULL
NF-	NULL
«	NULL
B	NULL
was	NULL
originally	NULL
described	NULL
as	NULL
a	NULL
DNA-binding	NULL
activity	NULL
that	NULL
recognized	NULL
a	NULL
sequence	NULL
in	NULL
the	NULL
Ig	NULL
k	NULL
light	NULL
chain	NULL
gene	NULL
enhancer	NULL
in	NULL
mature	NULL
B	NULL
cells	NULL
.	NULL
``	NULL

Subsequently	NULL
,	NULL
NE-	NULL
«	NULL
B	NULL
has	NULL
been	NULL
found	NULL
in	NULL
all	NULL
mature	NULL
hematopoietic	NULL
cell	NULL
lineages	NULL
(	NULL
eg	NULL
,	NULL
T	NULL
cells	NULL
,	NULL
``	NULL
``	NULL
monocytes	NULL
,	NULL
``	NULL
``	NULL
granulocytes	NULL
,	NULL
``	NULL
mast	NULL
cells	NULL
,	NULL
``	NULL
``	NULL
and	NULL
dendritic	NULL
cells*	NULL
``	NULL
)	NULL
and	NULL
has	NULL
been	NULL
recently	NULL
reported	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
erythropoiesis	NULL
.	NULL
``	NULL

However	NULL
,	NULL
the	NULL
expression	NULL
and	NULL
role	NULL
of	NULL
NF-kB	NULL
in	NULL
human	NULL
CD34*	NULL
bone	NULL
marrow	NULL
cells	NULL
are	NULL
currently	NULL
unknown	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
NF-kB	NULL
is	NULL
present	NULL
in	NULL
CD34	NULL
*	NULL
bone	NULL
marrow	NULL
cells	NULL
and	NULL
whether	NULL
NF-kB	NULL
is	NULL
required	NULL
for	NULL
colony	NULL
formation	NULL
.	NULL

The	NULL
results	NULL
of	NULL
these	NULL
studies	NULL
demonstrate	NULL
that	NULL
virtually	NULL
all	NULL
human	NULL
CD34*	NULL
bone	NULL
marrow	NULL
cells	NULL
contain	NULL
NF-kB	NULL
and	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
required	NULL
for	NULL
human	NULL
CD34+*	NULL
bone	NULL
marrow	NULL
cell	NULL
clonogenic	NULL
function	NULL
and	NULL
survival	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
purification	NULL
.	NULL

_	NULL
All	NULL
protocols	NULL
were	NULL
approved	NULL
by	NULL
the	NULL
University	NULL
of	NULL
Colorado	NULL
Health	NULL
Sciences	NULL
Center	NULL
Internal	NULL
Review	NULL
Board	NULL
,	NULL
and	NULL
samples	NULL
were	NULL
taken	NULL
with	NULL
informed	NULL
consent	NULL
from	NULL
normal	NULL
adult	NULL
volunteers	NULL
.	NULL

Human	NULL
bone	NULL
marrow	NULL
and	NULL
blood	NULL
were	NULL
obtained	NULL
by	NULL
aspiration	NULL
from	NULL
the	NULL
posterior	NULL
iliac	NULL
crest	NULL
and	NULL
venapuncture	NULL
,	NULL
respectively	NULL
.	NULL

Mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
using	NULL
Histopaque-1077	NULL
(	NULL
Sigma	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
AU	NULL
#	NULL
2	NULL
,	NULL
and	NULL
purification	NULL
of	NULL
individual	NULL
cell	NULL
subpopulations	NULL
was	NULL
achieved	NULL
using	NULL
a	NULL
high	NULL
magnetic	NULL
gradient	NULL
MiniMACS	NULL
purification	NULL
system	NULL
(	NULL
Miltenyi	NULL
,	NULL
Sun	NULL
Blood	NULL
,	NULL
Vol	NULL
93	NULL
,	NULL
No	NULL
10	NULL
(	NULL
May	NULL
15	NULL
)	NULL
,	NULL
1999	NULL
:	NULL
pp	NULL
3302-3308	NULL
AN	NULL
ESSENTIAL	NULL
ROLE	NULL
FOR	NULL
NF-	NULL
«	NULL
B	NULL
IN	NULL
HUMAN	NULL
CD34+	NULL
nyvale	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Because	NULL
NF-kB	NULL
is	NULL
known	NULL
to	NULL
be	NULL
expressed	NULL
in	NULL
B	NULL
lympho-cytes	NULL
,	NULL
``	NULL
we	NULL
used	NULL
the	NULL
pan-B-cell	NULL
antigen	NULL
CD19	NULL
to	NULL
isolate	NULL
CD34*	NULL
bone	NULL
marrow	NULL
cells	NULL
devoid	NULL
of	NULL
B	NULL
cells	NULL
(	NULL
CD34*CD19~	NULL
)	NULL
for	NULL
use	NULL
in	NULL
these	NULL
studies	NULL
.	NULL

CD19+*	NULL
cells	NULL
were	NULL
removed	NULL
and	NULL
detected	NULL
by	NULL
using	NULL
a	NULL
fluorescein	NULL
isothiocynate	NULL
(	NULL
FITC	NULL
)	NULL
-conjugated	NULL
anti-CD19	NULL
monoclonal	NULL
antibody	NULL
followed	NULL
by	NULL
anti-FITC	NULL
MicroBeads	NULL
(	NULL
Miltenyi	NULL
)	NULL
.	NULL

CD34*CD19~	NULL
cells	NULL
were	NULL
then	NULL
obtained	NULL
by	NULL
using	NULL
the	NULL
CD34	NULL
isolation	NULL
kit	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
were	NULL
purified	NULL
using	NULL
CD4	NULL
Microbeads	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
isolated	NULL
cells	NULL
was	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
analysis	NULL
(	NULL
Epics	NULL
752	NULL
;	NULL
Coulter	NULL
Electronics	NULL
,	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
.	NULL

-	NULL
Human	NULL
CD34	NULL
*CDI19~	NULL
bone	NULL
marrow	NULL
cells	NULL
were	NULL
either	NULL
used	NULL
directly	NULL
after	NULL
purification	NULL
or	NULL
for	NULL
selected	NULL
experiments	NULL
cultured	NULL
at	NULL
0.4	NULL
X	NULL
10°	NULL
cells/mL	NULL
for	NULL
18	NULL
hours	NULL
at	NULL
37°C	NULL
with	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
in	NULL
complete	NULL
media	NULL
(	NULL
RPMI-1640	NULL
,	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
100	NULL
mg/mL	NULL
streptomycin	NULL
,	NULL
100	NULL
U/mL	NULL
penicillin	NULL
,	NULL
and	NULL
2	NULL
mmol/L	NULL
L-glutamine	NULL
)	NULL
with	NULL
and	NULL
without	NULL
25	NULL
ng/mL	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
cytokines	NULL
,	NULL
or	NULL
NF-	NULL
«	NULL
B	NULL
nuclear	NULL
localization-sequence	NULL
(	NULL
NLS	NULL
)	NULL
peptides	NULL
before	NULL
use	NULL
in	NULL
the	NULL
EMSA	NULL
.	NULL

Cytokine	NULL
concentrations	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
were	NULL
identical	NULL
to	NULL
those	NULL
used	NULL
in	NULL
the	NULL
colony-forming	NULL
assays	NULL
and	NULL
was	NULL
used	NULL
at	NULL
50	NULL
ng/mL	NULL
.	NULL

Initial	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
NF-kB	NULL
NLS	NULL
peptides	NULL
purchased	NULL
from	NULL
Biomol	NULL
(	NULL
Ply-mouth	NULL
Meeting	NULL
,	NULL
PA	NULL
)	NULL
;	NULL
however	NULL
,	NULL
quality	NULL
control	NULL
issues	NULL
required	NULL
us	NULL
to	NULL
synthesize	NULL
these	NULL
peptides	NULL
based	NULL
on	NULL
the	NULL
published	NULL
sequences	NULL
.	NULL
``	NULL

The	NULL
NF-	NULL
«	NULL
B	NULL
NLS	NULL
peptides	NULL
were	NULL
used	NULL
at	NULL
100	NULL
ug/mL	NULL
.	NULL

Nuclear	NULL
protein	NULL
was	NULL
extracted	NULL
using	NULL
a	NULL
modified	NULL
Dignam	NULL
protocol	NULL
``	NULL
from	NULL
0.5	NULL
to	NULL
1	NULL
million	NULL
cells	NULL
per	NULL
treatment	NULL
group	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
using	NULL
a	NULL
BCA	NULL
protein	NULL
kit	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
and	NULL
the	NULL
nuclear	NULL
extracts	NULL
were	NULL
frozen	NULL
at	NULL
-80°C	NULL
until	NULL
used	NULL
.	NULL

An	NULL
NF-xB	NULL
probe	NULL
was	NULL
made	NULL
and	NULL
labeled	NULL
as	NULL
described	NULL
.	NULL

*	NULL
``	NULL
For	NULL
super-shift	NULL
samples	NULL
,	NULL
cellular	NULL
extracts	NULL
were	NULL
preincubated	NULL
with	NULL
appropriate	NULL
specific	NULL
antibodies	NULL
for	NULL
1	NULL
hour	NULL
to	NULL
overnight	NULL
at	NULL
4°C	NULL
.	NULL

Antihuman	NULL
p50	NULL
,	NULL
p52	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
rel	NULL
B	NULL
antibodies	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
and	NULL
antihuman	NULL
c-rel	NULL
and	NULL
a	NULL
second	NULL
antihuman	NULL
p65	NULL
antibody	NULL
were	NULL
purchased	NULL
from	NULL
Rockland	NULL
(	NULL
Gil-bertsville	NULL
,	NULL
PA	NULL
)	NULL
.	NULL

Nuclear	NULL
protein	NULL
(	NULL
4	NULL
ug	NULL
)	NULL
was	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
10	NULL
minutes	NULL
with	NULL
1	NULL
ug	NULL
dl-dC	NULL
,	NULL
4	NULL
uL	NULL
binding	NULL
buffer	NULL
(	NULL
20	NULL
mmol/L	NULL
HEPES	NULL
[	NULL
pH	NULL
7.9	NULL
]	NULL
40	NULL
mmol/L	NULL
KCI	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
0.05	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
1.6	NULL
mmol/L	NULL
MgC	NULL
]	NULL
;	NULL
)	NULL
1	NULL
mmol/L	NULL
DTT	NULL
,	NULL
and	NULL
deionized	NULL
water	NULL
for	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
19	NULL
uL	NULL
.	NULL

One	NULL
microliter	NULL
of	NULL
*°P-labeled	NULL
probe	NULL
(	NULL
~50,000	NULL
cpm	NULL
)	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
binding	NULL
reaction	NULL
was	NULL
continued	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
22°C	NULL
.	NULL

After	NULL
complex	NULL
formation	NULL
,	NULL
2	NULL
ug	NULL
of	NULL
loading	NULL
buffer	NULL
(	NULL
250	NULL
mmol/L	NULL
Tris	NULL
HCI	NULL
[	NULL
pH	NULL
7.51	NULL
,	NULL
0.2	NULL
%	NULL
bromophenol	NULL
blue	NULL
,	NULL
0.2	NULL
%	NULL
xylene	NULL
cyanol	NULL
,	NULL
40	NULL
%	NULL
glycerol	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
DNA-protein	NULL
complexes	NULL
,	NULL
and	NULL
the	NULL
sample	NULL
was	NULL
analyzed	NULL
by	NULL
electrophoresis	NULL
on	NULL
a	NULL
prerinsed	NULL
6	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
exposed	NULL
at	NULL
-80°C	NULL
to	NULL
Fuji	NULL
x-ray	NULL
film	NULL
(	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL

All	NULL
reported	NULL
experiments	NULL
were	NULL
repeated	NULL
at	NULL
least	NULL
3	NULL
times	NULL
.	NULL

Measuring	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Cells	NULL
were	NULL
exposed	NULL
to	NULL
25	NULL
ng/mL	NULL
PMA	NULL
and	NULL
1	NULL
ug/mL	NULL
ionomycin	NULL
or	NULL
buffer	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
37°C	NULL
in	NULL
RPMI-1640	NULL
containing	NULL
1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
BSA	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
,	NULL
followed	NULL
by	NULL
permeabilization	NULL
in	NULL
4	NULL
%	NULL
paraformaldehyde	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
pH	NULL
7.2	NULL
,	NULL
with	NULL
0.1	NULL
%	NULL
saponin	NULL
and	NULL
0.01	NULL
mol/L	NULL
HEPES	NULL
for	NULL
10	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
labeled	NULL
with	NULL
2	NULL
ug/mL	NULL
anti-NF-	NULL
«	NULL
B	NULL
antibody	NULL
(	NULL
IgGs	NULL
;	NULL
Boerhinger	NULL
Mannheim	NULL
,	NULL
Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
or	NULL
a	NULL
nonspecific	NULL
IgG	NULL
,	NULL
antibody	NULL
(	NULL
isotype	NULL
control	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
labeled	NULL
with	NULL
biotin-conjugated	NULL
goat	NULL
antimouse	NULL
IgGs	NULL
,	NULL
washed	NULL
2	NULL
times	NULL
,	NULL
and	NULL
subsequently	NULL
labeled	NULL
with	NULL
allophyocyanin	NULL
(	NULL
APC	NULL
)	NULL
-conjugated	NULL
strepavidin	NULL
.	NULL

After	NULL
the	NULL
final	NULL
wash	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
fixed	NULL
with	NULL
1	NULL
%	NULL
paraformaldehyde	NULL
and	NULL
stored	NULL
at	NULL
4°C	NULL
until	NULL
flow	NULL
cytometric	NULL
analysis	NULL
.	NULL

Flow	NULL
cytometry	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
MoFlo	NULL
system	NULL
(	NULL
Cytomation	NULL
,	NULL
Fort	NULL
Collins	NULL
,	NULL
CO	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
were	NULL
repeated	NULL
at	NULL
least	NULL
3	NULL
times	NULL
.	NULL

Colony-forming	NULL
assays	NULL
.	NULL

These	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
de-scribed	NULL
.	NULL
``	NULL

Briefly	NULL
,	NULL
CD34	NULL
*	NULL
bone	NULL
marrow	NULL
cells	NULL
were	NULL
purified	NULL
and	NULL
plated	NULL
in	NULL
35-mm	NULL
culture	NULL
dishes	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
3	NULL
to	NULL
4.5	NULL
X	NULL
10°	NULL
cells/mL	NULL
in	NULL
1	NULL
mL	NULL
of	NULL
modified	NULL
Iscove	NULL
's	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
100	NULL
mg/mL	NULL
streptomycin	NULL
,	NULL
100	NULL
U/mL	NULL
penicillin	NULL
,	NULL
2	NULL
mmol/L	NULL
L-glutamine	NULL
,	NULL
3303	NULL
50	NULL
umol/L	NULL
2-mercaptoethanol	NULL
,	NULL
1.2	NULL
%	NULL
(	NULL
wt/vol	NULL
)	NULL
methyl	NULL
cellulose	NULL
,	NULL
and	NULL
recombinant	NULL
cytokines	NULL
.	NULL

Each	NULL
cytokine	NULL
was	NULL
used	NULL
at	NULL
concentrations	NULL
experimentally	NULL
determined	NULL
to	NULL
produce	NULL
maximal	NULL
colony	NULL
formation	NULL
(	NULL
eg	NULL
,	NULL
5	NULL
ng/mL	NULL
GM-CSF	NULL
,	NULL
25	NULL
ng/mL	NULL
IL-3	NULL
,	NULL
25	NULL
ng/mL	NULL
G-CSF	NULL
,	NULL
25	NULL
ng/mL	NULL
M-CSF	NULL
,	NULL
25	NULL
ng/mL	NULL
stem	NULL
cell	NULL
factor	NULL
[	NULL
SCF	NULL
]	NULL
,	NULL
and	NULL
5	NULL
U/mL	NULL
EPO	NULL
)	NULL
.	NULL

All	NULL
chemicals	NULL
were	NULL
mixed	NULL
with	NULL
the	NULL
methyl	NULL
cellulose	NULL
media	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
cells	NULL
,	NULL
which	NULL
preceded	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
cytokines	NULL
.	NULL

All	NULL
cultures	NULL
were	NULL
maintained	NULL
at	NULL
37°C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
and	NULL
scored	NULL
on	NULL
day	NULL
14	NULL
of	NULL
culture	NULL
.	NULL

Five	NULL
plates	NULL
were	NULL
scored	NULL
for	NULL
each	NULL
treatment	NULL
group	NULL
,	NULL
and	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
+	NULL
1	NULL
standard	NULL
error	NULL
of	NULL
the	NULL
mean	NULL
(	NULL
SEM	NULL
)	NULL
.	NULL

Significant	NULL
differences	NULL
(	NULL
P	NULL
=.05	NULL
)	NULL
between	NULL
groups	NULL
were	NULL
determined	NULL
using	NULL
the	NULL
Student	NULL
's	NULL
test	NULL
(	NULL
Excel	NULL
4.0	NULL
;	NULL
Microsoft	NULL
Corp	NULL
,	NULL
Redmond	NULL
,	NULL
WA	NULL
)	NULL
.	NULL

All	NULL
reported	NULL
experiments	NULL
were	NULL
repeated	NULL
at	NULL
least	NULL
3	NULL
times	NULL
.	NULL

Apoptosis	NULL
assay	NULL
.	NULL

-	NULL
Purified	NULL
CD34	NULL
~CD19~	NULL
bone	NULL
marrow	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
NLS	NULL
fusion	NULL
peptide	NULL
,	NULL
control	NULL
peptide	NULL
,	NULL
or	NULL
buffer	NULL
in	NULL
RPMI-1640	NULL
media	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
at	NULL
37°C	NULL
for	NULL
16	NULL
hours	NULL
.	NULL

Apoptosis	NULL
was	NULL
measured	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
deoxynucleotidyl	NULL
transferase-mediated	NULL
dUTP	NULL
nick	NULL
end	NULL
labeling	NULL
(	NULL
TUNEL	NULL
;	NULL
In	NULL
Situ	NULL
Cell	NULL
Death	NULL
Detection	NULL
Kit	NULL
;	NULL
Boerhinger	NULL
Mannheim	NULL
)	NULL
for	NULL
each	NULL
sample	NULL
.	NULL

All	NULL
reported	NULL
experiments	NULL
were	NULL
repeated	NULL
at	NULL
least	NULL
3	NULL
times	NULL
.	NULL

RESULTS	NULL
Induction	NULL
of	NULL
NF-	NULL
«	NULL
B-specific	NULL
DNA-binding	NULL
activity	NULL
in	NULL
human	NULL
CD34*CD19~	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

-	NULL
CD34*	NULL
bone	NULL
marrow	NULL
cells	NULL
devoid	NULL
of	NULL
B	NULL
cells	NULL
(	NULL
CD34*CD197	NULL
)	NULL
were	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
,	NULL
because	NULL
NF-xB	NULL
is	NULL
known	NULL
to	NULL
be	NULL
expressed	NULL
in	NULL
B	NULL
lymphocytes	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL
``	NULL

CD34*CD19-	NULL
bone	NULL
marrow	NULL
cells	NULL
were	NULL
purified	NULL
and	NULL
cultured	NULL
overnight	NULL
with	NULL
and	NULL
without	NULL
PMA	NULL
.	NULL

EMSA	NULL
of	NULL
the	NULL
nuclear	NULL
extracts	NULL
demonstrate	NULL
no	NULL
detectable	NULL
NF-kB	NULL
specific	NULL
DNA-binding	NULL
in	NULL
the	NULL
unstimulated	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
PMA	NULL
exposure	NULL
induced	NULL
considerable	NULL
binding	NULL
(	NULL
Fig	NULL
1	NULL
)	NULL
.	NULL

Super-shift	NULL
O	NULL
-	NULL
10	NULL
CU	NULL
®	NULL
@	NULL
%	NULL
C	NULL
Antibodies	NULL
2	NULL
€	NULL
&	NULL
2	NULL
6	NULL
Nuclear	NULL
Extract	NULL
_+	NULL
+o	NULL
ko	NULL
oto	NULL
ook	NULL
o	NULL
$	NULL
o	NULL
o=	NULL
PMA	NULL
_-	NULL
Fook	NULL
o	NULL
oo	NULL
$	NULL
o	NULL
oRoo	NULL
$	NULL
o	NULL
=-wots	NULL
>	NULL
#	NULL
Shifted	NULL
}	NULL
%	NULL
#	NULL
Proteins	NULL
¥	NULL
f	NULL
LLL	NULL
Fig	NULL
1	NULL
.	NULL

PMA	NULL
induces	NULL
NF-	NULL
«	NULL
B	NULL
specific	NULL
DNA-binding	NULL
in	NULL
human	NULL
CD34*CD19~-	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

To	NULL
confirm	NULL
specificity	NULL
and	NULL
identify	NULL
which	NULL
Rel	NULL
family	NULL
members	NULL
may	NULL
be	NULL
binding	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
sequence	NULL
,	NULL
super-shift	NULL
EMSA	NULL
were	NULL
performed	NULL
with	NULL
antibodies	NULL
specific	NULL
for	NULL
human	NULL
p50	NULL
,	NULL
p65	NULL
,	NULL
p52	NULL
,	NULL
rel	NULL
B	NULL
,	NULL
and	NULL
c-rel	NULL
.	NULL

The	NULL
CD34+CD19~	NULL
cells	NULL
were	NULL
96.8	NULL
%	NULL
pure	NULL
for	NULL
this	NULL
representative	NULL
experiment	NULL
.	NULL

3304	NULL
EMSA	NULL
using	NULL
antibodies	NULL
specific	NULL
for	NULL
the	NULL
Rel	NULL
family	NULL
members	NULL
demonstrated	NULL
the	NULL
presence	NULL
of	NULL
p50	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
c-rel	NULL
by	NULL
the	NULL
appearance	NULL
of	NULL
shifted	NULL
bands	NULL
(	NULL
Fig	NULL
1	NULL
)	NULL
.	NULL

Although	NULL
antibodies	NULL
specific	NULL
for	NULL
p52	NULL
and	NULL
rel	NULL
B	NULL
did	NULL
not	NULL
cause	NULL
a	NULL
supershift	NULL
,	NULL
the	NULL
possibility	NULL
that	NULL
any	NULL
of	NULL
these	NULL
Rel	NULL
family	NULL
members	NULL
are	NULL
present	NULL
can	NULL
not	NULL
be	NULL
completely	NULL
excluded	NULL
due	NULL
the	NULL
heterogeneity	NULL
of	NULL
the	NULL
CD34*	NULL
cells	NULL
.	NULL

The	NULL
unreactive	NULL
antibodies	NULL
serve	NULL
as	NULL
an	NULL
Ig	NULL
control	NULL
demonstrating	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
p50	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
c-rel	NULL
antibod-ies	NULL
.	NULL

NF-KB	NULL
distribution	NULL
in	NULL
human	NULL
CD34*CD197~	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

We	NULL
evaluated	NULL
the	NULL
distribution	NULL
of	NULL
activated	NULL
NF-KB	NULL
in	NULL
both	NULL
PMA-stimulated	NULL
and	NULL
unstimulated	NULL
human	NULL
CD34*CD19-~-bone	NULL
marrow	NULL
and	NULL
CD4*	NULL
T	NULL
cells	NULL
by	NULL
flow	NULL
cytometry	NULL
using	NULL
a	NULL
monoclonal	NULL
antibody	NULL
that	NULL
recognizes	NULL
an	NULL
epitope	NULL
within	NULL
the	NULL
NE-	NULL
«	NULL
B	NULL
nuclear	NULL
localization	NULL
region	NULL
that	NULL
is	NULL
exposed	NULL
upon	NULL
activa-tion	NULL
.	NULL
``	NULL

''	NULL
Using	NULL
this	NULL
antibody	NULL
,	NULL
we	NULL
confirmed	NULL
the	NULL
results	NULL
of	NULL
the	NULL
EMSA	NULL
and	NULL
determined	NULL
that	NULL
activated	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
present	NULL
in	NULL
virtually	NULL
all	NULL
human	NULL
CD34*CD19~	NULL
cells	NULL
(	NULL
Fig	NULL
2	NULL
)	NULL
.	NULL

NF-KB	NULL
is	NULL
required	NULL
for	NULL
CD34*	NULL
cell	NULL
colony	NULL
formation	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
is	NULL
necessary	NULL
for	NULL
colony	NULL
formation	NULL
,	NULL
a	NULL
fusion	NULL
peptide	NULL
containing	NULL
the	NULL
NF-kB	NULL
NLS	NULL
and	NULL
a	NULL
membrane-permeable	NULL
hydrophobic	NULL
region	NULL
that	NULL
has	NULL
been	NULL
previously	NULL
demonstrated	NULL
to	NULL
specifically	NULL
prevent	NULL
NF-kB	NULL
nuclear	NULL
translocation	NULL
``	NULL
was	NULL
added	NULL
to	NULL
the	NULL
media	NULL
in	NULL
a	NULL
methyl	NULL
cellulose	NULL
colony-forming	NULL
assay	NULL
.	NULL

After	NULL
activation	NULL
of	NULL
NF-KB	NULL
,	NULL
its	NULL
NLS	NULL
associates	NULL
with	NULL
a	NULL
specific	NULL
NLS-receptor	NULL
,	NULL
resulting	NULL
in	NULL
transport	NULL
of	NULL
NF-KB	NULL
in	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

This	NULL
Cell	NULL
Number	NULL
NF-xB	NULL
Fig	NULL
2	NULL
.	NULL

Activated	NULL
NF-	NULL
«	NULL
B	NULL
measured	NULL
by	NULL
flow	NULL
cytometry	NULL
in	NULL
human	NULL
CD4+	NULL
peripheral	NULL
T	NULL
cells	NULL
(	NULL
[	NULL
A	NULL
]	NULL
unstimulated	NULL
,	NULL
[	NULL
B	NULL
]	NULL
stimulated	NULL
)	NULL
and	NULL
CD34+CD19-	NULL
bone	NULL
marrow	NULL
cells	NULL
(	NULL
[	NULL
C	NULL
]	NULL
unstimulated	NULL
,	NULL
[	NULL
D	NULL
]	NULL
stimulated	NULL
)	NULL
.	NULL

Stimulated	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
25	NULL
ng/mL	NULL
PMA	NULL
and	NULL
1	NULL
pg/mL	NULL
ionomycin	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
37°C	NULL
before	NULL
NF-	NULL
«	NULL
B	NULL
analysis	NULL
.	NULL

Activated	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
black	NULL
line	NULL
and	NULL
the	NULL
background	NULL
isotype	NULL
antibody	NULL
binding	NULL
is	NULL
a	NULL
gray	NULL
line	NULL
for	NULL
each	NULL
sample	NULL
.	NULL

The	NULL
monoclonal	NULL
antibody	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
specific	NULL
for	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
nuclear	NULL
localization	NULL
region	NULL
,	NULL
which	NULL
is	NULL
detected	NULL
only	NULL
if	NULL
NF-B	NULL
is	NULL
activated	NULL
.	NULL

The	NULL
CD4+	NULL
T	NULL
cells	NULL
and	NULL
CD34+CD19-	NULL
bone	NULL
marrow	NULL
cells	NULL
were	NULL
more	NULL
than	NULL
97	NULL
%	NULL
and	NULL
more	NULL
than	NULL
99	NULL
%	NULL
pure	NULL
,	NULL
respectively	NULL
.	NULL

PYATT	NULL
ET	NULL
AL	NULL
250	NULL
7	NULL
€	NULL
{	NULL
0	NULL
No	NULL
Peptide	NULL
3	NULL
app	NULL
j	NULL
A	NULL
Control	NULL
Peptide	NULL
8	NULL
.	NULL

BH	NULL
NF-kappa	NULL
B	NULL
NLS	NULL
Peptide	NULL
MEE	NULL
5	NULL
]	NULL
a	NULL
1	NULL
w	NULL
-	NULL
190	NULL
47	NULL
.2	NULL
4	NULL
C	NULL
I	NULL
9	NULL
-	NULL
50	NULL
:	NULL
*	NULL
*	NULL
o	NULL
I	NULL
o	NULL
1	NULL
0	NULL
t	NULL
T	NULL
GM-CSF	NULL
IL-3	NULL
-	NULL
M-CSF	NULL
G-CSF	NULL
IL-3	NULL
,	NULL
SCF	NULL
GM-CSF	NULL
,	NULL
Growth	NULL
Factors	NULL
EPO	NULL
Fig	NULL
3	NULL
.	NULL

-	NULL
Blocking	NULL
NF-	NULL
«	NULL
B	NULL
nuclear	NULL
translocation	NULL
inhibits	NULL
human	NULL
CD34+	NULL
bone	NULL
marrow	NULL
cell	NULL
colony	NULL
formation	NULL
.	NULL

Human	NULL
CD34+	NULL
bone	NULL
marrow	NULL
was	NULL
purified	NULL
(	NULL
>	NULL
96	NULL
%	NULL
pure	NULL
)	NULL
and	NULL
cultured	NULL
in	NULL
methyl	NULL
cellulose	NULL
medium	NULL
containing	NULL
various	NULL
cytokines	NULL
and	NULL
(	NULL
1	NULL
)	NULL
200	NULL
mg/mL	NULL
NF-	NULL
«	NULL
B	NULL
NLS	NULL
peptide	NULL
,	NULL
(	NULL
2	NULL
)	NULL
200	NULL
pg/mL	NULL
control	NULL
peptide	NULL
,	NULL
and	NULL
(	NULL
3	NULL
)	NULL
no	NULL
peptides	NULL
.	NULL

Error	NULL
bars	NULL
indicate	NULL
1	NULL
standard	NULL
error	NULL
of	NULL
mean	NULL
(	NULL
SEM	NULL
)	NULL
for	NULL
5	NULL
cultures	NULL
and	NULL
are	NULL
omitted	NULL
when	NULL
smaller	NULL
than	NULL
the	NULL
data	NULL
symbol	NULL
.	NULL

*Significant	NULL
decrease	NULL
compared	NULL
with	NULL
cultures	NULL
containing	NULL
the	NULL
control	NULL
peptide	NULL
(	NULL
P	NULL
=	NULL
.05	NULL
)	NULL
.	NULL

can	NULL
be	NULL
blocked	NULL
by	NULL
occupying	NULL
the	NULL
NF-kB	NULL
NLS-receptors	NULL
with	NULL
peptides	NULL
possessing	NULL
the	NULL
NF-kB	NULL
NLS	NULL
.	NULL

NF-kB	NULL
NLS	NULL
peptide	NULL
and	NULL
control	NULL
peptide	NULL
(	NULL
an	NULL
inactive	NULL
NF-kB	NULL
NLS	NULL
via	NULL
specific	NULL
amino	NULL
acid	NULL
substitutions	NULL
)	NULL
were	NULL
used	NULL
to	NULL
evaluate	NULL
the	NULL
effects	NULL
of	NULL
NF-kB	NULL
inhibition	NULL
on	NULL
colony-forming	NULL
unit	NULL
(	NULL
CFU	NULL
)	NULL
formation	NULL
using	NULL
human	NULL
CD34*	NULL
bone	NULL
marrow	NULL
cells	NULL
stimulated	NULL
by	NULL
either	NULL
GM-CSE	NULL
,	NULL
IL-3	NULL
,	NULL
M-CSF	NULL
,	NULL
G-CSF	NULL
,	NULL
or	NULL
a	NULL
mixture	NULL
of	NULL
IL-3	NULL
,	NULL
SCF	NULL
,	NULL
GM-CSF	NULL
,	NULL
and	NULL
EPO	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
NF-kB	NULL
is	NULL
either	NULL
required	NULL
for	NULL
cell	NULL
proliferation	NULL
and/or	NULL
required	NULL
for	NULL
clonogenic	NULL
cell	NULL
survival	NULL
.	NULL

GM-CSF	NULL
,	NULL
IL-3	NULL
,	NULL
and	NULL
TNF-a	NULL
,	NULL
but	NULL
not	NULL
M-CSF	NULL
and	NULL
G-CSF	NULL
,	NULL
activate	NULL
NF-KB	NULL
in	NULL
human	NULL
CD34*CD19~	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

EMSA	NULL
were	NULL
performed	NULL
to	NULL
determine	NULL
if	NULL
CFU	NULL
formation/	NULL
inhibition	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
correlates	NULL
with	NULL
NF-KB	NULL
activation/inhibition	NULL
,	NULL
respectively	NULL
,	NULL
using	NULL
the	NULL
cytokines	NULL
and	NULL
NF-kB	NULL
fusion	NULL
peptides	NULL
previously	NULL
described	NULL
.	NULL

As	NULL
a	NULL
positive	NULL
control	NULL
,	NULL
EMSA	NULL
was	NULL
also	NULL
performed	NULL
using	NULL
TNF-	NULL
«	NULL
,	NULL
because	NULL
it	NULL
is	NULL
a	NULL
well-documented	NULL
activator	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
.	NULL

The	NULL
results	NULL
of	NULL
these	NULL
experiments	NULL
demonstrate	NULL
that	NULL
GM-CSF	NULL
,	NULL
IL-3	NULL
,	NULL
and	NULL
TNF-	NULL
«	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
that	NULL
NF-KB	NULL
nuclear	NULL
localization	NULL
is	NULL
blocked	NULL
by	NULL
the	NULL
active	NULL
fusion	NULL
peptide	NULL
(	NULL
Fig	NULL
4	NULL
)	NULL
for	NULL
each	NULL
stimulus	NULL
.	NULL

G-CSF	NULL
and	NULL
M-CSF	NULL
did	NULL
not	NULL
activate	NULL
NF-kB	NULL
in	NULL
these	NULL
studies	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
previous	NULL
findings	NULL
using	NULL
other	NULL
cell	NULL
types	NULL
except	NULL
for	NULL
M-CSF	NULL
,	NULL
which	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
activate	NULL
NE-	NULL
«	NULL
B	NULL
in	NULL
macrophages	NULL
.	NULL

?	NULL
``	NULL

NF-KB	NULL
activation	NULL
by	NULL
cytokines	NULL
does	NULL
not	NULL
correlate	NULL
with	NULL
CFU	NULL
formation	NULL
,	NULL
because	NULL
there	NULL
are	NULL
NF-KB	NULL
activators	NULL
(	NULL
PMA	NULL
and	NULL
TNF-	NULL
«	NULL
@	NULL
)	NULL
that	NULL
do	NULL
not	NULL
induce	NULL
CFU	NULL
formation	NULL
and	NULL
there	NULL
are	NULL
cytokines	NULL
(	NULL
G-CSF	NULL
and	NULL
M-CSF	NULL
)	NULL
that	NULL
stimulate	NULL
CFU	NULL
formation	NULL
but	NULL
do	NULL
not	NULL
activate	NULL
NF-kB	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
there	NULL
were	NULL
several	NULL
experiments	NULL
in	NULL
which	NULL
there	NULL
was	NULL
a	NULL
baseline	NULL
NF-kB	NULL
activity	NULL
(	NULL
Fig	NULL
4A	NULL
,	NULL
C	NULL
,	NULL
and	NULL
D	NULL
)	NULL
suggesting	NULL
that	NULL
NE-	NULL
«	NULL
B	NULL
activity	NULL
may	NULL
be	NULL
constitutive	NULL
.	NULL

Although	NULL
NF-KB	NULL
activation	NULL
does	NULL
not	NULL
correlate	NULL
with	NULL
CFU	NULL
formation	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
inhibition	NULL
does	NULL
correlate	NULL
with	NULL
CFU	NULL
inhibition	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
AN	NULL
ESSENTIAL	NULL
ROLE	NULL
FOR	NULL
NF-	NULL
«	NULL
B	NULL
IN	NULL
HUMAN	NULL
CD34+	NULL
Nuclear	NULL
Extract	NULL
_	NULL
-	NULL
+	NULL
TNF-oq	NULL
_	NULL
-	NULL
_-NF-kB	NULL
NLS	NULL
Peptide	NULL
_	NULL
-	NULL
_	NULL
Control	NULL
Peptide	NULL
_	NULL
-	NULL
_	NULL
A	NULL
NF-KB	NULL
{	NULL
Nuclear	NULL
Extract	NULL
-+	NULL
IL-3	NULL
-	NULL
_	NULL
NF-kB	NULL
NLS	NULL
Peptide	NULL
_-	NULL
~	NULL
Fig	NULL
4	NULL
.	NULL

Cytokine	NULL
activation	NULL
of	NULL
Control	NULL
Peptide	NULL
-	NULL
_-NF-	NULL
«	NULL
B	NULL
in	NULL
CD34+CD19-	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

Human	NULL
CD34+CD19~	NULL
bone	NULL
marrow	NULL
was	NULL
purified	NULL
and	NULL
incubated	NULL
for	NULL
18	NULL
hours	NULL
at	NULL
37°C	NULL
C	NULL
with	NULL
each	NULL
cytokine/	NULL
peptide	NULL
combination	NULL
and	NULL
EMSA	NULL
was	NULL
per-formed	NULL
.	NULL

(	NULL
A	NULL
)	NULL
TNF-	NULL
«	NULL
,	NULL
(	NULL
B	NULL
)	NULL
GM-CSF	NULL
,	NULL
(	NULL
C	NULL
)	NULL
IL-3	NULL
,	NULL
and	NULL
(	NULL
E	NULL
)	NULL
a	NULL
combination	NULL
of	NULL
NF-KB	NULL
{	NULL
“	NULL
H	NULL
H	NULL
P	NULL
3305	NULL
*	NULL
Nuclear	NULL
Extract	NULL
*	NULL
*+	NULL
+	NULL
+	NULL
+o	NULL
to	NULL
oo+	NULL
Doy	NULL
_	NULL
GM-CSF	NULL
|	NULL
t	NULL
O+	NULL
O+	NULL
+	NULL
Loci	NULL
y	NULL
NF-kB	NULL
NLS	NULL
Peptide	NULL
_	NULL
t	NULL
_	NULL
~	NULL
+	NULL
=	NULL
Control	NULL
Peptide	NULL
_	NULL
-	NULL
_	NULL
~	NULL
_	NULL
~	NULL
_+	NULL
B	NULL
bi	NULL
-	NULL
bs	NULL
+	NULL
+	NULL
Nuclear	NULL
Extract	NULL
-	NULL
+	NULL
+	NULL
_+	NULL
+	NULL
+o	NULL
+	NULL
G-CSF	NULL
8	NULL
-o	NULL
+0	NULL
-	NULL
o	NULL
+0	NULL
-	NULL
M-CSF	NULL
-	NULL
t	NULL
0	NULL
-	NULL
o	NULL
$	NULL
o	NULL
-o	NULL
+	NULL
GM-CSF	NULL
-	NULL
_-	NULL
to	NULL
to	NULL
#	NULL
4	NULL
1	NULL
%	NULL
GM-CSF	NULL
,	NULL
IL-3	NULL
,	NULL
SCF	NULL
,	NULL
and	NULL
EPO	NULL
acti-	NULL
Nuclear	NULL
Extract	NULL
++	NULL
+-	NULL
+	NULL
vated	NULL
NF-kB	NULL
and	NULL
its	NULL
nuclear	NULL
translocation	NULL
could	NULL
be	NULL
blocked	NULL
IL	NULL
'	NULL
3+GM'CSF+SCF+EPO	NULL
~	NULL
+	NULL
ko	NULL
oA	NULL
by	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
NLS	NULL
peptide	NULL
.	NULL

(	NULL
D	NULL
)	NULL
NF-kB	NULL
NLS	NULL
Peptide	NULL
-	NULL
-	NULL
_+	NULL
M-CSF	NULL
and	NULL
G-CSF	NULL
did	NULL
not	NULL
acti-	NULL
Control	NULL
Peptide	NULL
-	NULL
_	NULL
-	NULL
_	NULL
-	NULL
_+	NULL
vate	NULL
NF-B	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
the	NULL
cells	NULL
for	NULL
experi-	NULL
ments	NULL
(	NULL
A	NULL
)	NULL
through	NULL
(	NULL
E	NULL
)	NULL
w	NULL
as	NULL
99.1	NULL
%	NULL
,	NULL
NF-KB	NULL
{	NULL
'	NULL
b	NULL
%	NULL
98.7	NULL
%	NULL
,	NULL
96.8	NULL
%	NULL
,	NULL
95.6	NULL
%	NULL
,	NULL
and	NULL
98.6	NULL
%	NULL
,	NULL
respectively	NULL
.	NULL

suggest	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
may	NULL
be	NULL
required	NULL
for	NULL
cell	NULL
survival	NULL
rather	NULL
than	NULL
proliferation	NULL
.	NULL

NF-KB	NULL
is	NULL
required	NULL
for	NULL
human	NULL
CD34*CD19~7	NULL
cell	NULL
survival	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
NF-kB	NULL
is	NULL
required	NULL
for	NULL
human	NULL
CD34*	NULL
cell	NULL
survival	NULL
,	NULL
apoptosis	NULL
was	NULL
measured	NULL
using	NULL
the	NULL
TUNEL	NULL
assay	NULL
in	NULL
human	NULL
CD34*CD19~	NULL
cells	NULL
incubated	NULL
for	NULL
16	NULL
hours	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
NLS	NULL
fusion	NULL
active	NULL
or	NULL
control	NULL
peptide	NULL
.	NULL

Cells	NULL
were	NULL
also	NULL
exposed	NULL
to	NULL
50	NULL
umol/L	NULL
etoposide	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
apoptosis	NULL
.	NULL

Inhibition	NULL
of	NULL
NF-kB	NULL
nuclear	NULL
translocation	NULL
using	NULL
50	NULL
ug/ml	NULL
peptide	NULL
resulted	NULL
in	NULL
68.1	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
undergoing	NULL
apoptosis	NULL
80	NULL
A	NULL
68.1	NULL
%	NULL
Apoptosis	NULL
Cell	NULL
Number	NULL
|	NULL
pf	NULL
f	NULL
O	NULL
OL	NULL
Oooo	NULL
oop	NULL
oppo	NULL
u	NULL
25	NULL
50	NULL
ug/ml	NULL
PBS	NULL
50	NULL
uM	NULL
Etoposide	NULL
NF-	NULL
«	NULL
B	NULL
N	NULL
eptide	NULL
n	NULL
LS	NULL
pepti	NULL
[	NULL
Z	NULL
]	NULL
Mutant	NULL
peptide	NULL
Apoptosis	NULL
(	NULL
Fig	NULL
5	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
NF-KB	NULL
is	NULL
necessary	NULL
for	NULL
human	NULL
CD34*CD19~	NULL
bone	NULL
marrow	NULL
cell	NULL
survival	NULL
.	NULL

DISCUSSION	NULL
We	NULL
demonstrate	NULL
here	NULL
that	NULL
NF-KB	NULL
is	NULL
present	NULL
in	NULL
human	NULL
CD34*CD19-	NULL
bone	NULL
marrow	NULL
cells	NULL
and	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
their	NULL
survival	NULL
.	NULL

Virtually	NULL
all	NULL
CD34*CD19~	NULL
,	NULL
human	NULL
bone	NULL
marrow	NULL
cells	NULL
contain	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
that	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
PMA	NULL
exposure	NULL
,	NULL
and	NULL
a	NULL
variety	NULL
of	NULL
cytokines	NULL
(	NULL
eg	NULL
,	NULL
GM-CSEB	NULL
,	NULL
IL-3	NULL
,	NULL
and	NULL
TNF-a	NULL
)	NULL
are	NULL
able	NULL
to	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

NF-KB	NULL
50	NULL
ug/ml	NULL
peptides	NULL
Fig	NULL
5	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
nuclear	NULL
translocation	NULL
induced	NULL
apoptosis	NULL
of	NULL
human	NULL
CD34+CD19~	NULL
human	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

The	NULL
deoxynucleotidyl	NULL
TUNEL	NULL
assay	NULL
was	NULL
performed	NULL
on	NULL
human	NULL
CD34+CD19-~	NULL
bone	NULL
marrow	NULL
cells	NULL
(	NULL
>	NULL
98	NULL
%	NULL
pure	NULL
)	NULL
after	NULL
(	NULL
A	NULL
)	NULL
16	NULL
or	NULL
(	NULL
B	NULL
)	NULL
18	NULL
hours	NULL
of	NULL
incubation	NULL
with	NULL
various	NULL
agents	NULL
.	NULL
``	NULL

The	NULL
controls	NULL
were	NULL
incubated	NULL
with	NULL
buffer	NULL
only	NULL
(	NULL
§	NULL
)	NULL
or	NULL
50	NULL
mol/L	NULL
etoposide	NULL
(	NULL
Z	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
NF-	NULL
«	NULL
B	NULL
NLS	NULL
peptide	NULL
(	NULL
MI	NULL
)	NULL
;	NULL
control	NULL
mutant	NULL
peptide	NULL
(	NULL
B	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Flow	NULL
cytogram	NULL
comparison	NULL
of	NULL
apoptosis	NULL
induced	NULL
by	NULL
50	NULL
g/mL	NULL
NF-	NULL
«	NULL
B	NULL
NLS	NULL
peptide	NULL
(	NULL
black	NULL
line	NULL
)	NULL
and	NULL
control	NULL
mutant	NULL
peptide	NULL
(	NULL
gray	NULL
line	NULL
)	NULL
show	NULL
n	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

3306	NULL
specificity	NULL
was	NULL
verified	NULL
by	NULL
antibody	NULL
recognition	NULL
in	NULL
both	NULL
the	NULL
supershift	NULL
EMSA	NULL
and	NULL
flow	NULL
cytometric	NULL
assays	NULL
and	NULL
by	NULL
competitive	NULL
inhibition	NULL
of	NULL
nuclear	NULL
translocation	NULL
using	NULL
a	NULL
peptide	NULL
specific	NULL
for	NULL
the	NULL
NF-kB	NULL
NLS	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
nuclear	NULL
translocation	NULL
induced	NULL
both	NULL
apoptosis	NULL
and	NULL
loss	NULL
of	NULL
clonogenic	NULL
function	NULL
in	NULL
human	NULL
CD34+*	NULL
cells	NULL
.	NULL

These	NULL
findings	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
established	NULL
role	NULL
of	NULL
NF-KB	NULL
as	NULL
a	NULL
secondary	NULL
messenger	NULL
for	NULL
GM-CSF	NULL
``	NULL
IL-3	NULL
,	NULL
``	NULL
and	NULL
TNF-	NULL
«	NULL
``	NULL
signal	NULL
transduction	NULL
as	NULL
measured	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
.	NULL

Contrary	NULL
to	NULL
other	NULL
studies	NULL
,	NULL
``	NULL
``	NULL
M-CSF	NULL
did	NULL
not	NULL
activate	NULL
NF-KB	NULL
in	NULL
our	NULL
system	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
proportion	NULL
of	NULL
the	NULL
CD34*CD19~	NULL
bone	NULL
marrow	NULL
cells	NULL
that	NULL
expressed	NULL
M-CSF	NULL
receptors	NULL
and	NULL
are	NULL
therefore	NULL
capable	NULL
of	NULL
responding	NULL
to	NULL
M-CSF	NULL
was	NULL
below	NULL
the	NULL
threshold	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
detection	NULL
in	NULL
the	NULL
EMSA	NULL
.	NULL

Another	NULL
explanation	NULL
is	NULL
that	NULL
the	NULL
M-CSF	NULL
signal	NULL
transduction	NULL
pathway	NULL
in	NULL
mature	NULL
or	NULL
peripheral	NULL
mononuclear	NULL
phagocytes	NULL
uses	NULL
NF-kB	NULL
,	NULL
``	NULL
``	NULL
whereas	NULL
CD34*CD19~	NULL
bone	NULL
marrow	NULL
cells	NULL
used	NULL
in	NULL
our	NULL
experiments	NULL
have	NULL
an	NULL
NF-	NULL
«	NULL
kB-independent	NULL
M-CSF	NULL
signal	NULL
transduction	NULL
pathway	NULL
.	NULL

Differences	NULL
in	NULL
activation	NULL
have	NULL
been	NULL
observed	NULL
for	NULL
IL-3	NULL
signaling	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
cell	NULL
type	NULL
.	NULL

Oster	NULL
et	NULL
al	NULL
``	NULL
``	NULL
did	NULL
not	NULL
detect	NULL
NF-kB	NULL
activation	NULL
after	NULL
IL-3	NULL
exposure	NULL
using	NULL
human	NULL
peripheral	NULL
mononuclear	NULL
phagocytes	NULL
,	NULL
but	NULL
Besangon	NULL
et	NULL
al	NULL
``	NULL
``	NULL
did	NULL
observe	NULL
IL-3-induced	NULL
activation	NULL
in	NULL
a	NULL
pro-B	NULL
IL-3-dependent	NULL
cell	NULL
line	NULL
(	NULL
Ba/F3	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
investigators	NULL
demonstrated	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
was	NULL
required	NULL
for	NULL
survival	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
both	NULL
NF-KB	NULL
activation	NULL
by	NULL
IL-3	NULL
and	NULL
a	NULL
requirement	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
CD34*CD19-	NULL
bone	NULL
marrow	NULL
cell	NULL
survival	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
Rel	NULL
family	NULL
members	NULL
are	NULL
sequentially	NULL
expressed	NULL
during	NULL
B-cell	NULL
development	NULL
and	NULL
that	NULL
ordered	NULL
expression	NULL
may	NULL
help	NULL
regulate	NULL
genes	NULL
that	NULL
are	NULL
involved	NULL
in	NULL
any	NULL
one	NULL
stage	NULL
of	NULL
differentiation	NULL
.	NULL
``	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
p65	NULL
distribution	NULL
in	NULL
CD34*	NULL
cells	NULL
suggests	NULL
that	NULL
p65	NULL
is	NULL
present	NULL
in	NULL
virtually	NULL
all	NULL
CD34*	NULL
cells	NULL
,	NULL
suggesting	NULL
a	NULL
role	NULL
for	NULL
NF-KB	NULL
in	NULL
supporting	NULL
cell	NULL
survival	NULL
rather	NULL
than	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
differentiation-specific	NULL
genes	NULL
.	NULL

The	NULL
distribution	NULL
of	NULL
c-rel	NULL
and	NULL
its	NULL
possible	NULL
role	NULL
in	NULL
stage-specific	NULL
differentiation	NULL
of	NULL
human	NULL
CD34+*	NULL
bone	NULL
marrow	NULL
cells	NULL
remains	NULL
unknown	NULL
.	NULL

A	NULL
number	NULL
of	NULL
different	NULL
mechanisms	NULL
may	NULL
explain	NULL
the	NULL
role	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
survival	NULL
of	NULL
CD34	NULL
*	NULL
cells	NULL
.	NULL

Inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
induce	NULL
apoptosis	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
,	NULL
and	NULL
in	NULL
B	NULL
lymphocytes	NULL
,	NULL
inhibition	NULL
of	NULL
NF-KB	NULL
is	NULL
reported	NULL
to	NULL
be	NULL
associated	NULL
with	NULL
a	NULL
decline	NULL
in	NULL
c-myc	NULL
expression	NULL
.	NULL
``	NULL

''	NULL
NF-kB	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
transactivate	NULL
c-myb	NULL
as	NULL
well	NULL
,	NULL
``	NULL
which	NULL
is	NULL
also	NULL
required	NULL
for	NULL
hematopoietic	NULL
cell	NULL
survival	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
positive	NULL
regulator	NULL
for	NULL
GM-CSF	NULL
production	NULL
,	NULL
``	NULL
and	NULL
GM-CSF	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
play	NULL
an	NULL
autocrine	NULL
role	NULL
in	NULL
colony	NULL
formation	NULL
.	NULL
``	NULL

The	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
a	NULL
variety	NULL
of	NULL
molecules	NULL
,	NULL
such	NULL
as	NULL
glucocorticoids	NULL
,	NULL
has	NULL
been	NULL
proposed	NULL
as	NULL
a	NULL
means	NULL
of	NULL
inducing	NULL
apoptosis	NULL
in	NULL
target	NULL
cell	NULL
populations	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
The	NULL
data	NULL
presented	NULL
here	NULL
indicate	NULL
that	NULL
NF-kB	NULL
activation	NULL
is	NULL
necessary	NULL
for	NULL
general	NULL
clonogenic	NULL
response	NULL
and	NULL
protects	NULL
against	NULL
apoptosis	NULL
in	NULL
CD34+*	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
results	NULL
,	NULL
proposed	NULL
strategies	NULL
involving	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
as	NULL
an	NULL
adjunct	NULL
to	NULL
anticancer	NULL
therapeutic	NULL
paradigms	NULL
should	NULL
be	NULL
approached	NULL
with	NULL
caution	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
potential	NULL
role	NULL
for	NULL
the	NULL
NF-KB	NULL
in	NULL
regulating	NULL
hematopoiesis	NULL
,	NULL
these	NULL
proteins	NULL
are	NULL
also	NULL
proto-oncogenes	NULL
``	NULL
and	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
transformation	NULL
process	NULL
in	NULL
several	NULL
types	NULL
of	NULL
cancer	NULL
.	NULL

The	NULL
avian	NULL
homologue	NULL
of	NULL
c-rel	NULL
,	NULL
v-rel	NULL
,	NULL
causes	NULL
the	NULL
PYATT	NULL
ET	NULL
AL	NULL
tumorigenicity	NULL
of	NULL
the	NULL
avian	NULL
reticuloendotheliosis	NULL
virus	NULL
(	NULL
REV-T	NULL
)	NULL
.	NULL
``	NULL

Human	NULL
T-lymphotrophic	NULL
virus-I	NULL
(	NULL
HTLV-I	NULL
)	NULL
-mediated	NULL
T-cell	NULL
leukemia	NULL
is	NULL
thought	NULL
to	NULL
involve	NULL
constitutive	NULL
NF-kB	NULL
activation	NULL
induced	NULL
by	NULL
the	NULL
tax	NULL
protein	NULL
.	NULL
``	NULL

P50/p65	NULL
NF-	NULL
«	NULL
B	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
the	NULL
p210	NULL
BCR-ABL	NULL
fusion	NULL
protein	NULL
that	NULL
mediates	NULL
transformation	NULL
in	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
(	NULL
CML	NULL
)	NULL
,	NULL
``	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
reportedly	NULL
a	NULL
critical	NULL
downstream	NULL
element	NULL
of	NULL
Ha-Ras	NULL
signaling	NULL
and	NULL
may	NULL
mediate	NULL
its	NULL
oncogenic	NULL
potential	NULL
.	NULL
``	NULL

''	NULL
In	NULL
conclusion	NULL
,	NULL
our	NULL
findings	NULL
demonstrate	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
p50	NULL
,	NULL
p65	NULL
,	NULL
c-rel	NULL
)	NULL
is	NULL
present	NULL
in	NULL
human	NULL
CD34*CD19~	NULL
bone	NULL
marrow	NULL
cells	NULL
and	NULL
suggest	NULL
that	NULL
it	NULL
is	NULL
required	NULL
for	NULL
colony	NULL
formation	NULL
and	NULL
cell	NULL
survival	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
NF-kB	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
human	NULL
CD34*	NULL
cell	NULL
signal	NULL
transduction	NULL
,	NULL
gene	NULL
expression	NULL
,	NULL
and	NULL
transformation	NULL
.	NULL

ACKNOWLEDGMENT	NULL
The	NULL
authors	NULL
thank	NULL
D.	NULL
Som	NULL
and	NULL
C.	NULL
Hodge	NULL
for	NULL
their	NULL
technical	NULL
assistance	NULL
and	NULL
K.	NULL
Helm	NULL
for	NULL
technical	NULL
assistance	NULL
with	NULL
flow	NULL
cytometry	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Bacuerle	NULL
PA	NULL
,	NULL
Henkel	NULL
T	NULL
:	NULL
Function	NULL
and	NULL
activation	NULL
of	NULL
NF-kB	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Annu	NULL
Rev	NULL
Immunol	NULL
12:141	NULL
,	NULL
1994	NULL
2	NULL
.	NULL

Thanos	NULL
D	NULL
,	NULL
Maniatis	NULL
T	NULL
:	NULL
NF-kappaB	NULL
:	NULL
A	NULL
lesson	NULL
in	NULL
family	NULL
values	NULL
.	NULL

Cell	NULL
80:529	NULL
,	NULL
1995	NULL
3	NULL
.	NULL

Matthews	NULL
JR	NULL
,	NULL
Hay	NULL
RT	NULL
:	NULL
Regulation	NULL
of	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
NE-	NULL
«	NULL
B	NULL
.	NULL

Int	NULL
J	NULL
Biochem	NULL
Cell	NULL
Biol	NULL
27:865	NULL
,	NULL
1995	NULL
4	NULL
.	NULL

Chytil	NULL
M	NULL
,	NULL
Verdine	NULL
GL	NULL
:	NULL
The	NULL
Rel	NULL
family	NULL
of	NULL
eukaryotic	NULL
transcription	NULL
factor	NULL
.	NULL

Curr	NULL
Opin	NULL
Struct	NULL
Biol	NULL
6:91	NULL
,	NULL
1996	NULL
5	NULL
.	NULL

Beg	NULL
AA	NULL
,	NULL
Baldwin	NULL
AS	NULL
Jr	NULL
:	NULL
Activation	NULL
of	NULL
multiple	NULL
NFE-	NULL
«	NULL
B/Rel	NULL
DNA-binding	NULL
complexes	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

Oncogene	NULL
9:1487	NULL
,	NULL
1994	NULL
6	NULL
.	NULL

Bacuerle	NULL
PA	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
NF-kappaB	NULL
:	NULL
Ten	NULL
years	NULL
after	NULL
.	NULL

Cell	NULL
87:13	NULL
,	NULL
1996	NULL
7	NULL
.	NULL

Bacuerle	NULL
PA	NULL
:	NULL
The	NULL
inducible	NULL
transcription	NULL
activator	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
Regulation	NULL
by	NULL
distinct	NULL
protein	NULL
subunits	NULL
.	NULL

Biochim	NULL
Biophys	NULL
Acta	NULL
1072:63	NULL
,	NULL
1991	NULL
8	NULL
.	NULL

Kunsch	NULL
C	NULL
,	NULL
Ruben	NULL
SM	NULL
,	NULL
Rosen	NULL
CA	NULL
:	NULL
Selection	NULL
of	NULL
optimal	NULL
«	NULL
B/Rel	NULL
DNA-binding	NULL
motifs	NULL
:	NULL
Interaction	NULL
of	NULL
both	NULL
subunits	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
with	NULL
DNA	NULL
is	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
12:4412	NULL
,	NULL
1992	NULL
9	NULL
.	NULL

Bacuerle	NULL
PA	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
A	NULL
65-kD	NULL
subunit	NULL
of	NULL
active	NULL
NF-B	NULL
is	NULL
required	NULL
for	NULL
inhibition	NULL
of	NULL
NF-xB	NULL
by	NULL
IkB	NULL
.	NULL

Genes	NULL
Dev	NULL
3:1689	NULL
,	NULL
1989	NULL
10	NULL
.	NULL

Sen	NULL
R	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Inducibility	NULL
of	NULL
«	NULL
immunoglobulin	NULL
enhancer-binding	NULL
protein	NULL
NF-kB	NULL
by	NULL
a	NULL
posttranslational	NULL
mechanism	NULL
.	NULL

Cell	NULL
47:921	NULL
,	NULL
1986	NULL
11	NULL
.	NULL

Baeuerle	NULL
PA	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
IB	NULL
:	NULL
A	NULL
specific	NULL
inhibitor	NULL
of	NULL
the	NULL
NE-B	NULL
transcription	NULL
factor	NULL
.	NULL

Science	NULL
242:540	NULL
,	NULL
1988	NULL
12	NULL
.	NULL

Siebenlist	NULL
U	NULL
,	NULL
Franzoso	NULL
G	NULL
,	NULL
Brown	NULL
K	NULL
:	NULL
Structure	NULL
,	NULL
regulation	NULL
and	NULL
function	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Annu	NULL
Rev	NULL
Cell	NULL
Biol	NULL
10:405	NULL
,	NULL
1994	NULL
13	NULL
.	NULL

Hiscott	NULL
J	NULL
,	NULL
Marois	NULL
J	NULL
,	NULL
Garoufalis	NULL
J	NULL
,	NULL
D	NULL
'	NULL
Addario	NULL
M	NULL
:	NULL
Characterization	NULL
of	NULL
a	NULL
functional	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
human	NULL
interleukin	NULL
1	NULL
beta	NULL
promoter	NULL
:	NULL
Evidence	NULL
for	NULL
a	NULL
positive	NULL
autoregulatory	NULL
loop	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
13:6231	NULL
,	NULL
1993	NULL
14	NULL
.	NULL

Ziegler-Heitbrock	NULL
HWL	NULL
,	NULL
Sternsdorf	NULL
T	NULL
,	NULL
Liese	NULL
J	NULL
,	NULL
Belohradsky	NULL
B	NULL
,	NULL
Weber	NULL
C	NULL
,	NULL
Wedel	NULL
A	NULL
,	NULL
Schreck	NULL
R	NULL
,	NULL
Bauerle	NULL
P	NULL
,	NULL
Strobel	NULL
M	NULL
:	NULL
Pyrrolidine	NULL
dithiocarbamate	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
mobilization	NULL
and	NULL
TNF	NULL
production	NULL
in	NULL
human	NULL
monocytes	NULL
.	NULL

J	NULL
Immunol	NULL
151:6986	NULL
,	NULL
1993	NULL
15	NULL
.	NULL

Mufioz	NULL
C	NULL
,	NULL
Pascual-Salcedo	NULL
D	NULL
,	NULL
Castellanos	NULL
MD	NULL
,	NULL
Alfranca	NULL
A	NULL
,	NULL
Aragonés	NULL
J	NULL
,	NULL
Vara	NULL
A	NULL
,	NULL
Redondo	NULL
JM	NULL
,	NULL
De	NULL
Land	NULL
@	NULL
zuri	NULL
MO	NULL
:	NULL
Pyrrolidine	NULL
dithiocarbamate	NULL
inhibits	NULL
the	NULL
production	NULL
of	NULL
interleukin-6	NULL
,	NULL
interleukin-8	NULL
,	NULL
and	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
by	NULL
human	NULL
endothelial	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
inflammatory	NULL
mediators	NULL
:	NULL
Modulation	NULL
of	NULL
AN	NULL
ESSENTIAL	NULL
ROLE	NULL
FOR	NULL
NF-kB	NULL
IN	NULL
HUMAN	NULL
CD34+	NULL
NF-kappaB	NULL
and	NULL
AP-1	NULL
transcription	NULL
factors	NULL
activity	NULL
.	NULL

Blood	NULL
88:3482	NULL
,	NULL
1996	NULL
16	NULL
.	NULL

Peng	NULL
HB	NULL
,	NULL
Rajavashisth	NULL
TB	NULL
,	NULL
Libby	NULL
P	NULL
,	NULL
Liao	NULL
JK	NULL
:	NULL
Nitric	NULL
oxide	NULL
inhibits	NULL
macrophage-colony	NULL
stimulating	NULL
factor	NULL
gene	NULL
transcription	NULL
in	NULL
vascular	NULL
endothelial	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:17050	NULL
,	NULL
1995	NULL
17	NULL
.	NULL

Musso	NULL
M	NULL
,	NULL
Ghiorzo	NULL
P	NULL
,	NULL
Fiorentini	NULL
P	NULL
,	NULL
Giuffrida	NULL
R	NULL
,	NULL
Ciotti	NULL
P	NULL
,	NULL
Garré	NULL
C	NULL
,	NULL
Ravazzolo	NULL
R	NULL
,	NULL
Bianchi-Scarra	NULL
G	NULL
:	NULL
An	NULL
upstream	NULL
positive	NULL
regulatory	NULL
element	NULL
in	NULL
human	NULL
GM-CSF	NULL
promoter	NULL
is	NULL
recognized	NULL
by	NULL
NF-kappaB/Rel	NULL
family	NULL
members	NULL
.	NULL

Biochem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
223:64	NULL
,	NULL
1996	NULL
18	NULL
.	NULL

Dunn	NULL
SM	NULL
,	NULL
Coles	NULL
LS	NULL
,	NULL
Lang	NULL
RK	NULL
,	NULL
Gerondakis	NULL
S	NULL
,	NULL
Vadas	NULL
MA	NULL
,	NULL
Shannon	NULL
MF	NULL
:	NULL
Requirement	NULL
for	NULL
nuclear	NULL
factor	NULL
(	NULL
NF	NULL
)	NULL
-kappa	NULL
B	NULL
p65	NULL
and	NULL
NF-interleukin-6	NULL
binding	NULL
elements	NULL
in	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
response	NULL
region	NULL
of	NULL
the	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
promoter	NULL
.	NULL

Blood	NULL
83:2469	NULL
,	NULL
1994	NULL
19	NULL
.	NULL

Lee-Huang	NULL
S	NULL
,	NULL
Lin	NULL
J-J	NULL
,	NULL
Kung	NULL
HF	NULL
,	NULL
Huang	NULL
PL	NULL
,	NULL
Lee	NULL
L	NULL
,	NULL
Huang	NULL
PL	NULL
:	NULL
The	NULL
human	NULL
eythropoietin-encoding	NULL
gene	NULL
contains	NULL
a	NULL
CAAT	NULL
box	NULL
,	NULL
TATA	NULL
boxes	NULL
and	NULL
other	NULL
transcriptional	NULL
regulatory	NULL
elements	NULL
in	NULL
the	NULL
5	NULL
flanking	NULL
region	NULL
.	NULL

Gene	NULL
128:227	NULL
,	NULL
1993	NULL
20	NULL
.	NULL

Young	NULL
HA	NULL
:	NULL
Regulation	NULL
of	NULL
interferon-gamma	NULL
gene	NULL
expression	NULL
.	NULL

J	NULL
Interferon	NULL
Cytokine	NULL
Res	NULL
16:563	NULL
,	NULL
1996	NULL
21	NULL
.	NULL

Lee	NULL
H	NULL
,	NULL
Arsura	NULL
M	NULL
,	NULL
Wu	NULL
M	NULL
,	NULL
Duyao	NULL
M	NULL
,	NULL
Buckler	NULL
AJ	NULL
,	NULL
Sonenshein	NULL
GE	NULL
:	NULL
Role	NULL
of	NULL
rel-related	NULL
factors	NULL
in	NULL
control	NULL
of	NULL
c-myc	NULL
gene	NULL
transcription	NULL
in	NULL
receptor-mediated	NULL
apoptosis	NULL
of	NULL
the	NULL
murine	NULL
B	NULL
cell	NULL
WEHI	NULL
231	NULL
line	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
181:1169	NULL
,	NULL
1995	NULL
22	NULL
.	NULL

Toth	NULL
CR	NULL
,	NULL
Hostutler	NULL
RF	NULL
,	NULL
Baldwin	NULL
AS	NULL
Jr	NULL
,	NULL
Bender	NULL
TP	NULL
:	NULL
Members	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
kappaB	NULL
family	NULL
transactivate	NULL
the	NULL
murine	NULL
c-myb	NULL
gene	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:7661	NULL
,	NULL
1995	NULL
23	NULL
.	NULL

Lowenthal	NULL
JW	NULL
,	NULL
Ballard	NULL
DW	NULL
,	NULL
Bohnlein	NULL
E	NULL
,	NULL
Greene	NULL
WC	NULL
:	NULL
Tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
induces	NULL
proteins	NULL
that	NULL
bind	NULL
specifically	NULL
to	NULL
kB-like	NULL
enhancer	NULL
elements	NULL
and	NULL
regulate	NULL
interleukin	NULL
2	NULL
receptor	NULL
«	NULL
-chain	NULL
gene	NULL
expression	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
86:2331	NULL
,	NULL
1989	NULL
24	NULL
.	NULL

McKean	NULL
DJ	NULL
,	NULL
Bell	NULL
M	NULL
,	NULL
Huntoon	NULL
C	NULL
,	NULL
Rastogi	NULL
S	NULL
,	NULL
Van	NULL
Norstrand	NULL
M	NULL
,	NULL
Podzorski	NULL
R	NULL
,	NULL
Nilson	NULL
A	NULL
,	NULL
Paya	NULL
C	NULL
:	NULL
IL-1	NULL
receptor	NULL
and	NULL
TCR	NULL
signals	NULL
synergize	NULL
to	NULL
activate	NULL
NE-kappaB-mediated	NULL
gene	NULL
transcription	NULL
.	NULL

Int	NULL
Immunol	NULL
7:9	NULL
,	NULL
1995	NULL
25	NULL
.	NULL

Brown	NULL
MC	NULL
,	NULL
Tomaras	NULL
GD	NULL
,	NULL
Vincenti	NULL
MP	NULL
,	NULL
Taffet	NULL
SM	NULL
:	NULL
Two	NULL
forms	NULL
of	NULL
NF-kappaB1	NULL
(	NULL
p105/p50	NULL
)	NULL
in	NULL
murine	NULL
macrophages	NULL
:	NULL
Differential	NULL
regulation	NULL
by	NULL
lipopolysaccharide	NULL
,	NULL
interleukin-2	NULL
,	NULL
and	NULL
interferon-gamma	NULL
.	NULL

J	NULL
Interferon	NULL
Cytokine	NULL
Res	NULL
17:295	NULL
,	NULL
1997	NULL
26	NULL
.	NULL

Gruss	NULL
H-J	NULL
,	NULL
Brach	NULL
MA	NULL
,	NULL
Herrmann	NULL
F	NULL
:	NULL
Involvement	NULL
of	NULL
nuclear	NULL
factor-kB	NULL
in	NULL
induction	NULL
of	NULL
the	NULL
interleukin-6	NULL
gene	NULL
by	NULL
leukemia	NULL
inhibitory	NULL
factor	NULL
.	NULL

Blood	NULL
80:2563	NULL
,	NULL
1992	NULL
27	NULL
.	NULL

Oster	NULL
W	NULL
,	NULL
Brach	NULL
MA	NULL
,	NULL
Gruss	NULL
H-J	NULL
,	NULL
Mertelsmann	NULL
R	NULL
,	NULL
Herrmann	NULL
F	NULL
:	NULL
Interleukin-1B	NULL
(	NULL
IL-16	NULL
)	NULL
expression	NULL
in	NULL
human	NULL
blood	NULL
mononuclear	NULL
phagocytes	NULL
is	NULL
differentially	NULL
regulated	NULL
by	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
,	NULL
M-CSF	NULL
,	NULL
and	NULL
IL-3	NULL
.	NULL

Blood	NULL
79:1260	NULL
,	NULL
1992	NULL
28	NULL
.	NULL

Hong	NULL
Y-H	NULL
,	NULL
Peng	NULL
H-B	NULL
,	NULL
Fata	NULL
VL	NULL
,	NULL
Liao	NULL
JK	NULL
:	NULL
Hydrogen	NULL
peroxide-mediated	NULL
transcriptional	NULL
induction	NULL
of	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
by	NULL
TGF-B1	NULL
.	NULL

J	NULL
Immunol	NULL
159:2418	NULL
,	NULL
1997	NULL
29	NULL
.	NULL

Besangon	NULL
F	NULL
,	NULL
Atfi	NULL
A	NULL
,	NULL
Gespach	NULL
C	NULL
,	NULL
Cayre	NULL
YE	NULL
,	NULL
Bourgeade	NULL
MF	NULL
:	NULL
Evidence	NULL
for	NULL
a	NULL
role	NULL
of	NULL
NF-kappaB	NULL
in	NULL
the	NULL
survival	NULL
of	NULL
hematopoietic	NULL
cells	NULL
mediated	NULL
by	NULL
interleukin	NULL
3	NULL
and	NULL
the	NULL
oncogenic	NULL
TEL/platelet-derived	NULL
growth	NULL
factor	NULL
receptor	NULL
b	NULL
fusion	NULL
protein	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
95:8081	NULL
,	NULL
1998	NULL
30	NULL
.	NULL

Beg	NULL
AA	NULL
,	NULL
Sha	NULL
WC	NULL
,	NULL
Bronson	NULL
RT	NULL
,	NULL
Ghosh	NULL
S	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Embryonic	NULL
lethality	NULL
and	NULL
liver	NULL
degeneration	NULL
in	NULL
mice	NULL
lacking	NULL
the	NULL
RelA	NULL
component	NULL
of	NULL
NF-kB	NULL
.	NULL

Nature	NULL
376:167	NULL
,	NULL
1995	NULL
31	NULL
.	NULL

Weih	NULL
F	NULL
,	NULL
Carrasco	NULL
D	NULL
,	NULL
Durham	NULL
SK	NULL
,	NULL
Barton	NULL
DS	NULL
,	NULL
Rizzo	NULL
CA	NULL
,	NULL
Ryseck	NULL
R-P	NULL
,	NULL
Lira	NULL
SA	NULL
,	NULL
Bravo	NULL
R	NULL
:	NULL
Multiorgan	NULL
inflammation	NULL
and	NULL
hematopoietic	NULL
abnormalities	NULL
in	NULL
mice	NULL
with	NULL
a	NULL
targeted	NULL
disruption	NULL
of	NULL
RelB	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
NF-kappaB/Re	NULL
!	NULL

family	NULL
.	NULL

Cell	NULL
80:331	NULL
,	NULL
1995	NULL
32	NULL
.	NULL

Sha	NULL
WC	NULL
,	NULL
Liou	NULL
H-C	NULL
,	NULL
Tuomanen	NULL
EI	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Targeted	NULL
disruption	NULL
of	NULL
the	NULL
p50	NULL
subunit	NULL
of	NULL
NF-kappaB	NULL
leads	NULL
to	NULL
multifocal	NULL
defects	NULL
in	NULL
immune	NULL
responses	NULL
.	NULL

Cell	NULL
80:321	NULL
,	NULL
1995	NULL
3307	NULL
33	NULL
.	NULL

Beg	NULL
AA	NULL
,	NULL
Sha	NULL
WC	NULL
,	NULL
Bronson	NULL
RT	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Constitutive	NULL
NF-kappaB	NULL
activation	NULL
,	NULL
enhanced	NULL
granulopoiesis	NULL
,	NULL
and	NULL
neonatal	NULL
lethality	NULL
in	NULL
IkappaBa-deficient	NULL
mice	NULL
.	NULL

Genes	NULL
Dev	NULL
9:2736	NULL
,	NULL
1995	NULL
34	NULL
.	NULL

Wang	NULL
CY	NULL
,	NULL
Mayo	NULL
MW	NULL
,	NULL
Baldwin	NULL
AS	NULL
Jr	NULL
:	NULL
TNF-	NULL
and	NULL
cancer	NULL
therapy-induced	NULL
apoptosis	NULL
:	NULL
Potentiation	NULL
by	NULL
inhibition	NULL
of	NULL
NF-kappaB	NULL
.	NULL

Science	NULL
274:784	NULL
,	NULL
1996	NULL
35	NULL
.	NULL

Van	NULL
Antwerp	NULL
DJ	NULL
,	NULL
Martin	NULL
SJ	NULL
,	NULL
Kafri	NULL
T	NULL
,	NULL
Green	NULL
DR	NULL
,	NULL
Verma	NULL
IM	NULL
:	NULL
Suppression	NULL
of	NULL
TNF-a-induced	NULL
apoptosis	NULL
by	NULL
NF-kappaB	NULL
.	NULL

Science	NULL
274:787	NULL
,	NULL
1996	NULL
36	NULL
.	NULL

Wu	NULL
M	NULL
,	NULL
Lee	NULL
H	NULL
,	NULL
Bellas	NULL
RE	NULL
,	NULL
Schauer	NULL
SL	NULL
,	NULL
Arsura	NULL
M	NULL
,	NULL
Rothstein	NULL
TL	NULL
,	NULL
Sherr	NULL
DH	NULL
,	NULL
Sonenshein	NULL
GE	NULL
:	NULL
Inhibition	NULL
of	NULL
NF-kB/rel	NULL
induces	NULL
apoptosis	NULL
of	NULL
murine	NULL
B	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
15:4682	NULL
,	NULL
1996	NULL
37	NULL
.	NULL

Sen	NULL
R	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Multiple	NULL
nuclear	NULL
factors	NULL
interact	NULL
with	NULL
the	NULL
immunogloulin	NULL
enhancer	NULL
sequences	NULL
.	NULL

Cell	NULL
46:705	NULL
,	NULL
1986	NULL
38	NULL
.	NULL

Griffin	NULL
GE	NULL
,	NULL
Leung	NULL
K	NULL
,	NULL
Folks	NULL
TM	NULL
,	NULL
Kunkel	NULL
S	NULL
,	NULL
Nabel	NULL
GJ	NULL
:	NULL
Activation	NULL
of	NULL
HIV	NULL
gene	NULL
expression	NULL
during	NULL
monocyte	NULL
differentiation	NULL
by	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Nature	NULL
339:70	NULL
,	NULL
1989	NULL
39	NULL
.	NULL

McDonald	NULL
PP	NULL
,	NULL
Bald	NULL
A	NULL
,	NULL
Cassatella	NULL
MA	NULL
:	NULL
Activation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
pathway	NULL
by	NULL
inflammatory	NULL
stimuli	NULL
in	NULL
human	NULL
neutrophils	NULL
.	NULL

Blood	NULL
89:3421	NULL
,	NULL
1997	NULL
40	NULL
.	NULL

Oh	NULL
CK	NULL
,	NULL
Metcalfe	NULL
DD	NULL
:	NULL
Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
TCA3	NULL
gene	NULL
in	NULL
mast	NULL
cells	NULL
after	NULL
FeeRI	NULL
cross-linking	NULL
.	NULL

J	NULL
Immunol	NULL
153:325	NULL
,	NULL
1994	NULL
41	NULL
.	NULL

Granelli-Piperno	NULL
A	NULL
,	NULL
Pope	NULL
M	NULL
,	NULL
Inaba	NULL
K	NULL
,	NULL
Steinman	NULL
RM	NULL
:	NULL
Coexpres-sion	NULL
of	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

l	NULL
and	NULL
Sp1	NULL
transcription	NULL
factors	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
l-induced	NULL
,	NULL
dendritic	NULL
cell-T-cell	NULL
syncytia	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
92:10944	NULL
,	NULL
1995	NULL
42	NULL
.	NULL

Zhang	NULL
MY	NULL
,	NULL
Sun	NULL
SC	NULL
,	NULL
Bell	NULL
L	NULL
,	NULL
Miller	NULL
BA	NULL
:	NULL
NF-kB	NULL
transcription	NULL
factors	NULL
are	NULL
involved	NULL
in	NULL
normal	NULL
erythropoiesis	NULL
.	NULL

Blood	NULL
91:4136	NULL
,	NULL
1998	NULL
43	NULL
.	NULL

Liou	NULL
H-C	NULL
,	NULL
Sha	NULL
WC	NULL
,	NULL
Scott	NULL
ML	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Sequential	NULL
induction	NULL
of	NULL
NJ-	NULL
«	NULL
B/Re	NULL
!	NULL

family	NULL
proteins	NULL
during	NULL
B-cell	NULL
terminal	NULL
differentiation	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
14:5349	NULL
,	NULL
1994	NULL
44	NULL
.	NULL

Lin	NULL
Y-Z	NULL
,	NULL
Yao	NULL
SY	NULL
,	NULL
Veach	NULL
RA	NULL
,	NULL
Torgerson	NULL
TR	NULL
,	NULL
Hawiger	NULL
J	NULL
:	NULL
Inhibition	NULL
of	NULL
nuclear	NULL
translocation	NULL
of	NULL
transcription	NULL
factor	NULL
NF-kappaB	NULL
by	NULL
a	NULL
synthetic	NULL
peptide	NULL
containing	NULL
a	NULL
cell	NULL
membrane-permeable	NULL
motif	NULL
and	NULL
nuclear	NULL
localization	NULL
sequence	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:14255	NULL
,	NULL
1995	NULL
45	NULL
.	NULL

Dignam	NULL
JD	NULL
,	NULL
Lebovitz	NULL
RM	NULL
,	NULL
Roeder	NULL
RG	NULL
:	NULL
Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
11:1475	NULL
,	NULL
1983	NULL
46	NULL
.	NULL

Pyatt	NULL
DW	NULL
,	NULL
Zheng	NULL
JH	NULL
,	NULL
Stillman	NULL
WS	NULL
,	NULL
Irons	NULL
RD	NULL
:	NULL
Inorganic	NULL
lead	NULL
activates	NULL
NF-kappaB	NULL
in	NULL
primary	NULL
human	NULL
CD4*	NULL
T	NULL
lymphocytes	NULL
.	NULL

Biochem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
227:380	NULL
,	NULL
1996	NULL
47	NULL
.	NULL

Irons	NULL
RD	NULL
,	NULL
Le	NULL
AT	NULL
,	NULL
Som	NULL
DB	NULL
,	NULL
Stillman	NULL
WS	NULL
:	NULL
2	NULL
'	NULL
3'-dideoxycytidine-induced	NULL
thymic	NULL
lymphoma	NULL
correlates	NULL
with	NULL
species-specific	NULL
suppression	NULL
of	NULL
a	NULL
subpopulation	NULL
of	NULL
primitive	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
in	NULL
mouse	NULL
but	NULL
not	NULL
rat	NULL
or	NULL
human	NULL
bone	NULL
marrow	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
95:2777	NULL
,	NULL
1995	NULL
48	NULL
.	NULL

Kaltschmidt	NULL
C	NULL
,	NULL
Kaltschmidt	NULL
B	NULL
,	NULL
Henkel	NULL
T	NULL
,	NULL
Stockinger	NULL
H	NULL
,	NULL
Bacuerle	NULL
PA	NULL
:	NULL
Selective	NULL
recognition	NULL
of	NULL
the	NULL
activated	NULL
form	NULL
of	NULL
transcription	NULL
factor	NULL
NF-kappaB	NULL
by	NULL
a	NULL
monoclonal	NULL
antibody	NULL
.	NULL

Biol	NULL
Chem	NULL
Hoppe	NULL
Seyler	NULL
376:9	NULL
,	NULL
1995	NULL
49	NULL
.	NULL

Wu	NULL
M	NULL
,	NULL
Arsura	NULL
M	NULL
,	NULL
Bellas	NULL
RE	NULL
,	NULL
Fitzgerald	NULL
MJ	NULL
,	NULL
Lee	NULL
H	NULL
,	NULL
Schauer	NULL
SL	NULL
,	NULL
Sherr	NULL
DH	NULL
,	NULL
Sonenshein	NULL
GE	NULL
:	NULL
Inhibition	NULL
of	NULL
c-myc	NULL
expression	NULL
induces	NULL
apoptosis	NULL
of	NULL
WEHI	NULL
231	NULL
murine	NULL
B	NULL
cells	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
16:5015	NULL
,	NULL
1996	NULL
50	NULL
.	NULL

Mucenski	NULL
ML	NULL
,	NULL
McLain	NULL
K	NULL
,	NULL
Kier	NULL
AB	NULL
,	NULL
Swerdlow	NULL
SH	NULL
,	NULL
Schreiner	NULL
CM	NULL
,	NULL
Miller	NULL
TA	NULL
,	NULL
Pictryga	NULL
DW	NULL
,	NULL
Scott	NULL
WJ	NULL
Jr	NULL
,	NULL
Potter	NULL
SS	NULL
:	NULL
A	NULL
functional	NULL
c-myb	NULL
gene	NULL
is	NULL
required	NULL
for	NULL
normal	NULL
murine	NULL
fetal	NULL
hepatic	NULL
hematopoiesis	NULL
.	NULL

Cell	NULL
65:677	NULL
,	NULL
1991	NULL
51	NULL
.	NULL

Thomas	NULL
RS	NULL
,	NULL
Tymms	NULL
MJ	NULL
,	NULL
McKinlay	NULL
LH	NULL
,	NULL
Shannon	NULL
MF	NULL
,	NULL
Seth	NULL
A	NULL
,	NULL
Kola	NULL
I	NULL
:	NULL
;	NULL
ETS1	NULL
,	NULL
NFkappaB	NULL
and	NULL
AP1	NULL
synergistically	NULL
transactivate	NULL
the	NULL
human	NULL
GM-CSF	NULL
promoter	NULL
.	NULL

Oncogene	NULL
14:2845	NULL
,	NULL
1997	NULL
52	NULL
.	NULL

Pech	NULL
N	NULL
,	NULL
Hermine	NULL
O	NULL
,	NULL
Goldwasser	NULL
E	NULL
:	NULL
Further	NULL
study	NULL
of	NULL
internal	NULL
autocrine	NULL
regulation	NULL
of	NULL
multipotent	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Blood	NULL
82:1502	NULL
,	NULL
1993	NULL
53	NULL
.	NULL

Gilmore	NULL
TD	NULL
,	NULL
Koedood	NULL
M	NULL
,	NULL
Piffat	NULL
KA	NULL
,	NULL
White	NULL
DW	NULL
:	NULL
Rel/NF-kappaB/	NULL
IkappaB	NULL
proteins	NULL
and	NULL
cancer	NULL
.	NULL

Oncogene	NULL
13:1367	NULL
,	NULL
1996	NULL
54	NULL
.	NULL

Beauparlant	NULL
P	NULL
,	NULL
Kwan	NULL
I	NULL
,	NULL
Bitar	NULL
R	NULL
,	NULL
Chou	NULL
P	NULL
,	NULL
Koromilas	NULL
AE	NULL
,	NULL
3308	NULL
Sonenberg	NULL
N	NULL
,	NULL
Hiscott	NULL
J	NULL
:	NULL
Disruption	NULL
of	NULL
IkappaBa	NULL
regulation	NULL
by	NULL
antisense	NULL
RNA	NULL
expression	NULL
leads	NULL
to	NULL
malignant	NULL
transformation	NULL
.	NULL

Oncogene	NULL
9:3189	NULL
,	NULL
1994	NULL
55	NULL
.	NULL

Bose	NULL
HR	NULL
Jr	NULL
:	NULL
The	NULL
Rel	NULL
family	NULL
:	NULL
Models	NULL
for	NULL
transcriptional	NULL
regulation	NULL
and	NULL
oncogenic	NULL
transformation	NULL
.	NULL

Biochim	NULL
Biophys	NULL
Acta	NULL
1114	NULL
:	NULL
1	NULL
,	NULL
1992	NULL
56	NULL
.	NULL

Hiscott	NULL
J	NULL
,	NULL
Petropoulos	NULL
L	NULL
,	NULL
Lacoste	NULL
H	NULL
:	NULL
Molecular	NULL
interactions	NULL
between	NULL
HTLV-1	NULL
tax	NULL
protein	NULL
and	NULL
the	NULL
NF-kappaB/kappaB	NULL
transcription	NULL
complex	NULL
.	NULL

Virology	NULL
214:3	NULL
,	NULL
1995	NULL
PYATT	NULL
ET	NULL
AL	NULL
57	NULL
.	NULL

Hamdane	NULL
M	NULL
,	NULL
David-Cordonnier	NULL
MH	NULL
,	NULL
D'Halluin	NULL
JC	NULL
:	NULL
Activation	NULL
of	NULL
p65	NULL
NF-kappaB	NULL
protein	NULL
by	NULL
p210°C®*®	NULL
``	NULL
in	NULL
myeloid	NULL
cell	NULL
line	NULL
(	NULL
p2108C®A8	NULL
activates	NULL
p65	NULL
NF-kappaB	NULL
)	NULL
.	NULL

Oncogene	NULL
15:2267	NULL
,	NULL
1997	NULL
58	NULL
.	NULL

Finco	NULL
TS	NULL
,	NULL
Westwick	NULL
JK	NULL
,	NULL
Norris	NULL
JL	NULL
,	NULL
Beg	NULL
AA	NULL
,	NULL
Der	NULL
CJ	NULL
,	NULL
Baldwin	NULL
AS	NULL
Jr	NULL
:	NULL
Oncogenic	NULL
Ha-Ras-induced	NULL
signaling	NULL
activates	NULL
NF-kappaB	NULL
transcriptional	NULL
activity	NULL
,	NULL
which	NULL
is	NULL
required	NULL
for	NULL
cellular	NULL
transformation	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:24113	NULL
,	NULL
1997	NULL

